Schedule 1—Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

Note: See sections 5 and 6.

Permissible ingredients and requirements

Column 1

Column 2

Column 3

Column 4

Item

Ingredient Name

Purpose

Specific requirements

3636

P-ALPHA-DIMETHYL STYRENE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3637

P-ANISIC ACID

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.3%.

 

3638

PADIMATE O

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 8%.

When used in primary sunscreen products, the following warning statements are required on the label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

3639

PADINA PAVONICA THALLUS PHYTOSTEROLS

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.01%.

 

3640

PAEONIA LACTIFLORA

A, E, H

 

3641

PAEONIA OBOVATA

A, H

 

3642

PAEONIA SUFFRUTICOSA

A, E, H

 

3643

PAEONIA VEITCHII

A, H

 

3644

PALIURUS SPINA-CHRISTI

A, H

 

3645

PALLADIUM

H

Only for use as an active homoeopathic ingredient.

 

3646

PALM FRUIT OIL

A, E, H

 

3647

PALM GLYCERIDES

E

 

3648

PALM KERNEL OIL

A, E, H

 

3649

PALM TOCOTRIENOLS COMPLEX

A, H

 

3650

PALMARIA PALMATA

A, H

 

3651

PALMAROSA OIL

A, E, H

 

3652

PALMIDROL

A

Only permitted for use in medicines limited to oral routes of administration.

The maximum recommended daily dose of the medicine must not provide more than 600 mg of palmidrol.

The following warning statements (or words to the same effect) are required on the medicine label:

- (ANALG) 'The medicine may interact with other prescription analgesic medicines, please consult your healthcare practitioner before use.'

- (ADULT) ‘Adults only.’

- (21DAYS) ‘Not to be used for more than 21 consecutive days.’

 

3653

PALMITIC ACID

E

 

3654

PALMITOLEIC ACID-RICH FATTY ACID ETHYL ESTERS

A

 

3655

PALMITOYL DIPEPTIDE-7

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.002%.

 

3656

PALMITOYL HYDROXYPROPYLTRIMONIUM AMYLOPECTIN/GLYCERIN CROSSPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.01%

 

3657

PALMITOYL OLIGOPEPTIDE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.002%.

 

3658

PALMITOYL PENTAPEPTIDE-3

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.0005%.

 

3659

PALMITOYL TETRAPEPTIDE-3

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.001%.

 

3660

PANAX GINSENG

A, E, H

 

3661

PANAX JAPONICUS

A, H

 

3662

PANAX NOTOGINSENG

A, H

 

3663

PANAX PSEUDOGINSENG

A, H

 

3664

PANAX QUINQUEFOLIUS

A, H

 

3665

PANICUM MILIACEUM

A, H

 

3666

PANTETHINE

E

Only for use in topical medicines for dermal application.

 

3667

PANTHENOL

A, E

 

3668

PANTHENYL ETHYL ETHER

E

Only for use in topical medicines for dermal application.

 

3669

PANTOLACTONE

E

 

3670

PANTOTHENIC ACID

A, E

When used topically, the concentration in the medicine must be no more than 0.1%.

 

3671

PANTOTHENIC ACID POLYPEPTIDE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

3672

PAPAIN

A, E

 

3673

PAPER

E

Only for use in topical medicines for dermal application.

 

3674

PAPRIKA OLEORESIN

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3675

PARA-CRESOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3676

PARA-CRESYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3677

PARA-CRESYL ISOBUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3678

PARA-CRESYL PHENYLACETATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3679

PARA-CYMENE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3680

PARA-ETHOXYBENZALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3681

PARA-ETHYL CRESOXYACETATE

E

Para-ethyl cresoxyacetate must only be included in medicines when in combination with other permitted ingredients as a fragrance proprietary excipient formulation.

The total concentration of the fragrance proprietary excipient formulation containing para-ethyl cresoxyacetate must not be more than 1% of the total medicine.

 

3682

PARA-ETHYLPHENOL

E

Permitted for use only in combination with other permitted ingredients as part of a flavour proprietary excipient formulation.

The maximum recommended daily dose must contain no more than 0.12 mg of para-ethylphenol.

The total flavour proprietary excipient formulation in a medicine must be no more than 5%.

 

3683

PARA-HYDROXY BENZALACETONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3684

PARA-HYDROXYBENZOIC ACID

E

 

3685

PARA-MENTHA-8-THIOL-3-ONE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3686

PARA-METHYL ACETOPHENONE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3687

PARA-METHYL ANISOLE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3688

PARA-METHYL DIMETHYLBENZYL CARBINOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3689

PARA-PROPYL ANISOLE

E

Para-propyl anisole must only be included in medicines when in combination with other permitted ingredients as a fragrance and/or flavour proprietary excipient formulation.

 The total concentration of fragrance proprietary excipient formulations containing para-propyl anisole must not be more than 1% of the total medicine.

The total concentration of flavour proprietary excipient formulations containing para-propyl anisole must not be more than 5% of the total medicine.

 

3690

PARA-TERT-BUTYLCYCLOHEXYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3691

PARA-TERT-BUTYLPHENYL-ALPHA-METHYLHYDROCINNAMIC ALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3692

PARA-TOLUALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3693

PARA-TOLYL ACETALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3694

PARAMERIA LAEVIGATA

A, H

 

3695

PARIETARIA JUDAICA

A, H

 

3696

PARIS POLYPHYLLA

A, H

 

3697

PARIS QUADRIFOLIA

A, H

 

3698

PARSLEY HERB DRY

A, E, H

 

3699

PARSLEY HERB OIL

A, E, H

 

3700

PARSLEY HERB POWDER

A, E, H

 

3701

PARSLEY SEED OIL

A, E, H

 

3702

PARTHENOCISSUS TRICUSPIDATA

A, H

 

3703

PARTIALLY DEHYDRATED LIQUID SORBITOL

E

Sorbitol is a mandatory component of partially dehydrated liquid sorbitol.

Permitted for use only as part of the capsule in medicines where the dosage form is a soft capsule.

 

3704

PARTIALLY HYDROGENATED SOYA OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in the medicine must be no more than 5%.

 

3705

PARTIALLY REFINED PORPHYRA YEZOENSIS CYTOPLASM EXTRACT

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.00002%.

 

3706

PASPALUM NOTATUM

A, H

 

3707

PASSIFLORA CAERULEA

A, H

 

3708

PASSIFLORA EDULIS

E

 

3709

PASSIFLORA HERB DRY

A, H

 

3710

PASSIFLORA INCARNATA

A, E, H

 

3711

PATCHOULI OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3712

PATENT BLUE V

E

Permitted for use only as a colour in medicines limited to topical and oral routes of administration.

 

3713

PATENT BLUE V ALUMINIUM LAKE

E

Permitted for use only as a colour in medicines limited to topical and oral routes of administration.

 

3714

PATRINIA SCABIOSIFOLIA

A, H

 

3715

PATRINIA VILLOSA

A, H

 

3716

PAULLINIA CUPANA

A, E, H

Caffeine is a mandatory component of Paullinia cupana.

When the medicine is packaged for supply as a divided preparation and is for internal use or oral application, the medicine must not contain a concentration of total caffeine greater than 33%.

When for internal use or oral application, the maximum recommended daily dose of the medicine must provide no more than 400 mg of total caffeine.

When the medicine is packaged for supply as an undivided preparation and is for internal use or oral application, the medicine must not contain a concentration of total caffeine greater than 1%.

When the medicine is for internal use or oral application, a maximum recommended dose of the medicine must not provide more than 100 mg of total caffeine within a 3 hour period.

When the maximum recommended daily dose of the medicine provides greater than 10 mg of total caffeine and the medicine is for internal use or oral application, the following warning statements are required on the label:

- (ADULT) 'Adults only' (or words to that effect).

- (CAFF) 'Contains [state quantity per dosage unit or per mL or per gram of product] total caffeine [per dosage unit or per mL or per gram]. A cup of instant coffee contains approximately 80mg of caffeine.'

- (CAFFPREG) ‘Caffeine intake more than 200 mg per day is not recommended during pregnancy or breastfeeding.’

When the maximum recommended daily dose of the medicine provides greater than 80 mg of total caffeine and the medicines is for internal use or oral application, the following warning statements are required on the label:

- (CAFFLMT) 'Limit the use of caffeine-containing products (including tea and coffee) when taking this product.'

- (CAFFCYP) ‘Caffeine interacts with enzyme CYP1A2 in the liver. Consult your health professional before taking with other medicines’ (or words to that effect).

 

3717

PAULLINIA PINNATA

A, H

 

3718

PAWPAW

E

 

3719

PEA

E

 

3720

PEA STARCH

E

 

3721

PEACH

E

 

3722

PEAR

E

 

3723

PECAN

E

 

3724

PECTIN

A, E

 

3725

PEG-10 DIMETICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or damaged skin.

The concentration in the medicine must be no more than 4.0%.

 

3726

PEG-10 SOYA STEROL

E

Only for use in topical medicines for dermal application.

 

3727

PEG-100 STEARATE

E

Only for use in topical medicines for dermal application.

 

3728

PEG-12 DILAURATE

E

 

3729

PEG-12 DIMETICONE/PPG-20 CROSSPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2%.

 

3730

PEG-120 METHYL GLUCOSE DIOLEATE

E

Only for use in topical medicines for dermal application.

 

3731

PEG-120 STEARATE

E

Only for use in topical medicines for dermal application.

 

3732

PEG-15 COCAMINE

E

Only for use in topical medicines for dermal application.

 

3733

PEG-150 DISTEARATE

E

Only for use in topical medicines for dermal application.

 

3734

PEG-20 ALMOND GLYCERIDES

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

3735

PEG-20 METHYL GLUCOSE DISTEARATE

E

Only for use in topical medicines for dermal application.

 

3736

PEG-20 METHYL GLUCOSE SESQUISTEARATE

E

Only for use in topical medicines for dermal application.

 

3737

PEG-20 SORBITAN ISOSTEARATE

E

Only for use in topical medicines for dermal application.

 

3738

PEG-20 STEARATE

E

Only for use in topical medicines for dermal application.

 

3739

PEG-25 PABA

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 10%.

When used in primary sunscreen products, the following warning statements are required on the label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

3740

PEG-30 DIPOLYHYDROXYSTEARATE

E

Only for use in topical medicines for dermal application.

 

3741

PEG-30 STEARATE

E

Only for use in topical medicines for dermal application.

 

3742

PEG-35 CASTOR OIL

E

 

3743

PEG-4 DILAURATE

E

Only for use in topical medicines for dermal application.

 

3744

PEG-4 LAURATE

E

Only for use in topical medicines for dermal application.

Dioxane and Ethylene oxide are mandatory components of PEG-4 laurate.

The concentration of Dioxane in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%.

The concentration of Ethylene oxide in the medicine must be no more than 1 mg/kg or 1 mg/L or 0.0001%.

 

3745

PEG-4 STEARATE

E

Only for use in topical medicines for dermal application.

 

3746

PEG-40 CASTOR OIL

E

 

3747

PEG-40 HYDROGENATED CASTOR OIL

E

 

3748

PEG-40 SORBITAN DIISOSTEARATE

E

Only for use in topical medicines for dermal application.

Dioxane and Ethylene oxide are mandatory components of PEG-40 sorbitan diisostearate.

The concentration of Dioxane in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%.

The concentration of Ethylene oxide in the medicine must be no more than 1 mg/kg or 1 mg/L or 0.0001%.

 

3749

PEG-40 STEARATE

E

Only for use in topical medicines for dermal application.

 

3750

PEG-45/DODECYL GLYCOL COPOLYMER

E

Only for use in topical medicines for dermal application.

 

3751

PEG-5 GLYCERYL STEARATE

E

Only for use in topical medicines for dermal application.

 

3752

PEG-50 STEARATE

E

Only for use in topical medicines for dermal application.

 

3753

PEG-55 PROPYLENE GLYCOL OLEATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.6%.

 

3754

PEG-6 LAURAMIDE

E

Only for use in topical medicines for dermal application.

 

3755

PEG-60 ALMOND GLYCERIDES

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration when used in medicines applied directly to the skin must be no more than 10%.

The concentration when used in bath oil medicines must be no more than 30%.

 

3756

PEG-60 GLYCERYL ISOSTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

3757

PEG-60 HYDROGENATED CASTOR OIL

E

Only for use in topical medicines for dermal application.

 

3758

PEG-7 COCAMIDE

E

Only for use in topical medicines for dermal application.

 

3759

PEG-7 GLYCERYL COCOATE

E

Only for use in topical medicines for dermal application.

 

3760

PEG-7 HYDROGENATED CASTOR OIL

E

Only for use in topical medicines for dermal application.

 

3761

PEG-75 LANOLIN

E

Only for use in topical medicines for dermal application.

 

3762

PEG-75 STEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.5%.

 

3763

PEG-8 CETYL DIMETHICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.0005%.

 

3764

PEG-8 DILAURATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4%.

 

3765

PEG-8 DISTEARATE

E

Only for use in topical medicines for dermal application.

 

3766

PEG-8 LAURATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4%.

The levels of possible impurities such as ethylene oxide (and related material) must be kept below the level of detection.

 

3767

PEG-8 PROPYLENE GLYCOL COCOATE

E

 

3768

PEG-8 STEARATE

E

Only for use in topical medicines for dermal application.

 

3769

PEG-9 POLYDIMETHYLSILOXYETHYL DIMETICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 3.5%.

 

3770

PEG/PPG-14/7 DIMETHYL ETHER

E

Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 7%.

 

3771

PEG/PPG-18/18 DIMETHICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

3772

PELARGONIUM GRAVEOLENS

A, E, H

 

3773

PELLITORINE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3774

PELTIGERA CANINA

A, H

 

3775

PENICILLIUM EXPANSUM

A, H

 

3776

PENNYROYAL OIL

E

D-Pulegone/Pulegone is a mandatory component of Pennyroyal Oil.

The concentration of D Pulegone/ Pulegone in the medicine must be no more than 4%.

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in the medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in the medicine must be no more than 1%.

When the medicine is for a use other than topical, the maximum recommended daily dose must be no more than 50 mg of Pennyroyal Oil.

 

3777

PENTAERYTHRITYL TETRA-DI-T-BUTYL HYDROXYHYDROCINNAMATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.018%

 

3778

PENTAERYTHRITYL TETRAISOSTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 61%.

 

3779

PENTAERYTHRITYL TETRALAURATE

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 80%.

 

3780

PENTAMETHYLHEPTENONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3781

PENTANE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3782

PENTASODIUM ETHYLENEDIAMINE TETRAMETHYLENE PHOSPHONATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

3783

PENTYLENE GLYCOL

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

3784

PEPPER BLACK

E, H

 

3785

PEPPER OIL TERPENELESS

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3786

PEPPERMINT AMERICAN EXT.

E

Menthol is a mandatory component of peppermint american ext.

When the medicine is for topical use for dermal application:

a) the medicine must not be intended for use in the eye or on damaged skin;

b) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;

c) the following warning statement is required on the medicine label:

- (EYE) Avoid contact with eyes (or words to that effect).

d) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use.

e) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label:

– (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.

When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

3787

PEPPERMINT LEAF DRY

A, E, H

Menthol is a mandatory component of peppermint leaf dry.

When the medicine is for topical use for dermal application:

(i) the medicine must not be intended for use in the eye or on damaged skin;

(ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;

(iii) the following warning statement is required on the medicine label:

- (EYE) Avoid contact with eyes (or words to that effect).

(iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use.

(v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label:

– (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.

When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

3788

PEPPERMINT LEAF POWDER

A, E, H

Menthol is a mandatory component of peppermint leaf powder.

When the medicine is for topical use for dermal application:

(i) the medicine must not be intended for use in the eye or on damaged skin;

(ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;

(iii) the following warning statement is required on the medicine label:

- (EYE) Avoid contact with eyes (or words to that effect).

(iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use.

(v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label:

– (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.

When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

3789

PEPPERMINT OIL

A, E, H

Menthol is a mandatory component of peppermint oil.

When the medicine is for topical use for dermal application:

(i) the medicine must not be intended for use in the eye or on damaged skin;

(ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;

(iii) the following warning statement is required on the medicine label:

- (EYE) Avoid contact with eyes (or words to that effect).

(iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use.

(v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label:

– (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.

When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

3790

PEPPERMINT OIL TERPENELESS

E

Permitted for use only in combination with other permitted ingredients as a flavour proprietary excipient formulation or fragrance proprietary excipient formulation.

The total flavour proprietary excipient formulation in a medicine must be no more than 5%.

The total fragrance proprietary excipient formulation in a medicine must be no more 1%.

Menthol is a mandatory component of peppermint oil terpeneless.

When the medicine is for topical use for dermal application:

i) the medicine must not be intended for use in the eye or on damaged skin;

ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;

iii) the following warning statement is required on the medicine label:

- (EYE) Avoid contact with eyes (or words to that effect).

iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use.

v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label:

– (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.

When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

3791

PEPPERMINT OIL TERPENES AND TERPENOIDS

E

Permitted for use only in combination with other permitted ingredients as a flavour proprietary excipient formulation.

The total flavour proprietary excipient formulation in a medicine must be no more than 5%.

Menthol is a mandatory component of peppermint oil terpenes and terpenoids.

When the medicine is for topical use for dermal application:

i) the medicine must not be intended for use in the eye or on damaged skin;

ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;

iii) the following warning statement is required on the medicine label:

- (EYE) Avoid contact with eyes (or words to that effect).

iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use.

v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label:

– (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.

When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

3792

PERFLUOROPOLYMETHYLISOPROPYL ETHER

E

Only for use in topical medicines for dermal application.

 

3793

PERHYDRO-3,6-DIMETHYL-BENZO [B] FURAN-2-ONE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3794

PERILLA FRUTESCENS

A, E, H

 

3795

PERILLALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3796

PERLITE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

3797

PERMETHRIN

E

The total concentration of permethrin in the medicine must not be more than 2%.

 

3798

PERSEA AMERICANA

A, E, H

 

3799

PERSIC OIL

A, E, H

Amygdalin and Hydrocyanic acid are mandatory components of Persic oil.

The concentration of amygdalin in the medicine must be no more than 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

3800

PERSICARIA CHINENSIS

A, H

 

3801

PERSICARIA TINCTORIA

A, H

 

3802

PERU BALSAM

A, E, H

 

3803

PERU BALSAM OIL

A, E, H

 

3804

PETITGRAIN MANDARIN OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour

The final concentration of the oil in the flavour does not exceed 30%

If used in a flavour the total flavour concentration in a medicine must be no more than 5%

 

3805

PETITGRAIN OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3806

PETITGRAIN OIL CITRONNIER

E

Permitted for use only in combination with other permitted ingredients as part of a fragrance proprietary excipient formulation.

When included in a medicine for use on the lips the concentration of petitgrain oil citronnier must be no more than 0.1%.

When included in dermal creams for infant use the concentration of petitgrain oil citronnier must be no more than 0.5%

The total fragrance proprietary excipient formulation in a medicine must be no more than 1%.

 

3807

PETITGRAIN OIL PARAGUAY

A, E, H

When used internally, oxedrine is a mandatory component of petitgrain oil paraguay.

The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams.

 

3808

PETITGRAIN OIL TERPENELESS

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3809

PETROSELINUM CRISPUM

A, E, H

 

3810

PEUCEDANUM PRAERUPTORUM

A, E, H

 

3811

PEUMUS BOLDUS

A, H

Volatile oil components (of Peumus boldus) is a mandatory component.

The maximum recommended daily dose must be no more than 100 mg of volatile oil components (of Peumus boldus).

 

3812

PHALARIS ARUNDINACEA

A, H

 

3813

PHALARIS CANARIENSIS

A, H

 

3814

PHASEOLUS COCCINEUS

A, H

 

3815

PHASEOLUS VULGARIS

A, H

 

3816

PHELLINUS ROBINIAE

A, E, H

 

3817

PHELLODENDRON AMURENSE

A, E, H

 

3818

PHELLODENDRON CHINENSE

A, H

 

3819

PHENACETIN

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 0.1%.

 

3820

PHENETHYL 2-METHYLBUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3821

PHENETHYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3822

PHENETHYL ALCOHOL

E

Permitted for use only:

a) in topical medicines for dermal application; and

b) for internal use in combination with other permitted ingredients as part of a flavour proprietary excipient formulation.

The total flavour proprietary excipient formulation concentration in a medicine must be no more than 5%.

 

3823

PHENETHYL BENZOATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 6%.

 

3824

PHENETHYL DIMETHICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.2%

 

3825

PHENETHYL ISOAMYL ETHER

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used as in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3826

PHENETHYL ISOBUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3827

PHENETHYL ISOVALERATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3828

PHENETHYL PHENYLACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3829

PHENETHYL SALICYLATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3830

PHENOL

E

Only for use in topical medicines for dermal application.

The concentration of phenol in the medicine must be no more than 1%.

 

3831

PHENOXYACETALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3832

PHENOXYETHANOL

E

Only for use in topical medicines for dermal application.

The concentration of phenoxyethanol in the preparation must not exceed 15%.

 

3833

PHENOXYETHYL ISOBUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3834

PHENOXYETHYLPARABEN

E

Only for use in topical medicines for dermal application.

 

3835

PHENYL DIMETHICONE

E

Only for use in topical medicines for dermal application.

 

3836

PHENYL TRIMETHICONE

E

Only for use in topical medicines for dermal application.

 

3837

PHENYLACETALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3838

PHENYLACETALDEHYDE DIMETHYL ACETAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3839

PHENYLACETALDEHYDE GLYCERYLACETAL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3840

PHENYLACETIC ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3841

PHENYLALANINE

A, E

When the maximum recommended daily dose of the medicine provides more than 500 mg phenylalanine, the following warning statement is required on the medicine label:

- (PREGNT2) 'Do not use if pregnant or likely to become pregnant'.

 

3842

PHENYLBENZIMIDAZOLE SULFONIC ACID

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 4%.

When used in primary sunscreen products, the following warning statements are required on the label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

3843

PHENYLETHYL BUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3844

PHENYLETHYL CAPROATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3845

PHENYLETHYL CAPRYLATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3846

PHENYLETHYL CINNAMATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3847

PHENYLETHYL FORMATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3848

PHENYLETHYL METHYLETHYL CARBINOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3849

PHENYLETHYL PROPIONATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3850

PHENYLETHYL TIGLATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3851

PHENYLISOPROPYL DIMETICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

3852

PHENYLPROPANOL

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.16%.

 

3853

PHLEUM PRATENSE

A, H

Only permitted in preparations other than phleum pratense pollen extract.

 

3854

PHLOXINE B

E

Permitted for use only as a colour in medicines limited to topical and oral routes of administration.

 

3855

PHLOXINE B ALUMINIUM LAKE

E

Permitted for use only as a colour in medicines limited to topical and oral routes of administration.

 

3856

PHOENIX DACTYLIFERA

A, E, H

 

3857

PHOSPHATIDYL CHOLINE

E

 

3858

PHOSPHOLIPIDS

E

Only for use in topical medicines for dermal application and not intended for use in the eye.

The concentration in the medicine must be no more than 20%.

 

3859

PHOSPHORIC ACID

E, H

The concentration in liquid medicines must be no more than 15%.

 

3860

PHOSPHORUS

H

Only for use as an active homoeopathic ingredient.

The total concentration of phosphorus in the medicine must not be more than 1 mg/kg or 1 mg/L or 0.0001%.

 

3861

PHOTINIA SERRULATA

A, H

 

3862

PHRAGMITES AUSTRALIS

A, H

 

3863

PHYLLANTHUS AMARUS

A, H

 

3864

PHYLLANTHUS EMBLICA

A, E, H

When used as an excipient, only for use in topical medicines for dermal application.

 

3865

PHYLLOSTACHYS NIGRA

A, E, H

 

3866

PHYSALIS ALKEKENGI

A, H

 

3867

PHYSALIS PUBESCENS

A, H

 

3868

PHYTANTRIOL

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 0.5%.

 

3869

PHYTOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3870

PHYTOLACCA AMERICANA

A, H

The maximum recommended daily dose of the medicine must contain no more than 1mg of the equivalent dry herb.

 

3871

PHYTOMENADIONE

A, E

 

3872

PHYTOSPHINGOSINE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

3873

PHYTOSTERYL/OCTYLDODECYL LAUROYL GLUTAMATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

3874

PICEA ABIES

A, H

 

3875

PICEA MARIANA

A, H

 

3876

PICRASMA EXCELSA

A, E, H

 

3877

PICRORRHIZA KURROA

A, E, H

 

3878

PIGMENT BLUE 15

E

Permitted for use only as a colour for topical and dental use.

The concentration in medicine must be no more than 0.003%.

 

3879

PIGMENT BLUE 15:1

E

Permitted for use only as a colour for topical use.

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.21%.

 

3880

PIGMENT GREEN 7

E

Permitted for use only as a colour for topical and dental use.

When for dental use, the concentration in the medicine must be no more than 0.003%.

When for topical use, the concentration in the medicine must be no more than 0.17%.

 

3881

PIGMENT RED 4

E

Permitted for use only as a colour for topical use.

 

3882

PIGMENT RED 53

E

Permitted for use only as a colour for topical use.

 

3883

PIGMENT RED 57

E

Permitted for use only as a colour for topical use.

 

3884

PIGMENT RED 57 ALUMINIUM LAKE

E

Permitted for use only as a colour for topical use.

 

3885

PIGMENT RED 57 BARIUM LAKE

E

Permitted for excipient use as a colour in topical medicines for dermal application.

Not to be included in medicines intended for use in the eye.

 

3886

PIGMENT RED 63

E

Permitted for use only as a colour for topical use.

 

3887

PIGMENT WHITE 26

E

Permitted for use only as a colour for topical use.

 

3888

PIGMENT YELLOW 12

E

Permitted for use only as a colour for topical use.

 

3889

PILOCARPUS JABORANDI

A, H

Pilocarpine is a mandatory component of Pilocarpus  jaborandi.

The concentration of pilocarpine in the medicine must be no more than 0.025%.

 

3890

PILOCARPUS MICROPHYLLUS

A, H

Pilocarpine is a mandatory component of Pilocarpus microphyllus.

The concentration of pilocarpine in the medicine must be no more than 0.025%.

 

3891

PILOCARPUS PINNATIFOLIUS

A, H

Pilocarpine is a mandatory component of Pilocarpus pinnatifolius.

The concentration of pilocarpine in the medicine must be no more than 0.025%.

 

3892

PIMENTA FRUIT OIL

A, E, H

 

3893

PIMENTA LEAF OIL

A, E, H

 

3894

PIMENTA OFFICINALIS

A, E, H

 

3895

PIMENTA RACEMOSA

A, E, H

When the plant preparation for Pimenta racemosa is an oil and the concentration of this oil in the medicine is more than 25%, the nominal capacity of the container must be no more than 25 mL.

When the plant preparation for Pimenta racemosa is an oil, the concentration of this oil in the medicine is more than 25%, and  the nominal capacity of the container is more than 15 mL, a restricted flow insert must be fitted on the container.

When the plant preparation for Pimenta racemosa is an oil, the concentration of this oil in the medicine is more than 25%, and the nominal capacity of the container is more than 15 mL but no more than 25 mL, a child resistant closure and restricted flow insert must be fitted on the container.

The medicine requires the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or word to that effect)

- (NTAKEN) 'Not to be taken'.

 

3896

PIMPINELLA ANISUM

A, E, H

When the plant preparation for Pimpinella anisum is an oil or distillate and the concentration of this oil or distillate in the medicine is more than 50%:

a) the nominal capacity of the container must not be more than 50 millilitres; and

b) a restricted flow insert must be fitted on the container; and

c) the medicine requires the following warning statement on the medicine label:

- (CHILD) ‘Keep out of reach of children’ (or words to that effect).

 

3897

PIMPINELLA SAXIFRAGA

A, E, H

 

3898

PINE NEEDLE OIL SCOTCH

A, E, H

 

3899

PINE NEEDLE OIL TERPENELESS

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3900

PINE OIL AROMATIC

A, E, H

 

3901

PINE OIL PUMILIO

A, E, H

 

3902

PINEAPPLE

E

 

3903

PINEAPPLE OILS

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3904

PINELLIA TERNATA

A, H

 

3905

PINUS CONTORTA

A, E, H

 

3906

PINUS ELLIOTTII

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3907

PINUS MASSONIANA

A, E, H

When the plant preparation is oil or distillate the total concentration of Pinus massoniana oil or distillate in the preparation must be no more than 25%.

 

3908

PINUS MONTICOLA

A, E, H

 

3909

PINUS MUGO

A, E, H

 

3910

PINUS PALUSTRIS

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3911

PINUS PINASTER

A, E, H

When the plant preparation is oil or distillate the total concentration of Pinus pinaster oil or distillate in the preparation must be no more than 25%.

 

3912

PINUS PONDEROSA

A, E, H

 

3913

PINUS RADIATA

A, E, H

 

3914

PINUS STROBUS

A, E, H

 

3915

PINUS SYLVESTRIS

A, E, H

 

3916

PINUS TABULIFORMIS

A, E, H

 

3917

PINUS YUNNANENSIS

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3918

PIPENZOLATE BROMIDE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3919

PIPER CHABA

A, E, H

 

3920

PIPER CUBEBA

A, E, H

 

3921

PIPER KADSURA

A, E, H

 

3922

PIPER LONGUM

A, E, H

 

3923

PIPER METHYSTICUM

A, H

Kavalactones (of Piper methysticum) is a mandatory component of Piper methysticum.

Only for oral use when the dosage form is 'tablet' or 'capsule'; or when the container type is 'tea bag'.

When used in oral medicines, the maximum daily dose of kavalactones (of Piper methysticum) must be no more than 250 mg.

If the dosage form is tablet or capsule then the quantity of kavalactones (of Piper methysticum) must be no more than 125 mg per tablet or capsule.

Oral medicines containing more than 25 mg of kavalactones (of Piper methysticum) per dose require the following warning statement on the medicine label:

- (PIPER) 'Not for prolonged use. If symptoms persist - seek advice from a healthcare practitioner. Not recommended for pregnant or lactating women (or words to that effect). May harm the liver'.

The plant part must be root or rhizome.

When for oral use, the medicine may only contain dried whole or peeled root or rhizome or aqueous dispersions or aqueous extracts of whole or peeled root or rhizome.

When for topical use on the rectum, vagina or throat, the medicine may only contain dried whole or peeled root or rhizome or aqueous dispersions or aqueous extracts of whole or peeled root or rhizome.

When the container type is tea bag the maximum quantity per tea bag must be no more than 3 grams of dried whole or peeled root or rhizomes.

 

3924

PIPER NIGRUM

A, E, H

 

3925

PIPER SARMENTOSUM

A, E, H

 

3926

PIPERINE

E

Permitted for use only in combination with other permitted ingredients as a flavour proprietary formulation.

The total flavour proprietary formulation in a medicine must not be more than 5% and the concentration of piperine in the medicine must not be more than 0.15%.

 

3927

PIPERITONE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3928

PIPERONAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3929

PIPERONYL ACETONE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used as a flavour the total flavour concentration in a medicine must be no more than 5%.

If used as in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3930

PIPERONYL BUTOXIDE

E

Only for use in topical medicines for dermal application.

 

3931

PIROCTONE OLAMINE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1% in wash-on/wash-off medicines and 0.5% in leave-on medicines.

 

3932

PISCIDIA PISCIPULA

A, E, H

 

3933

PISTACIA LENTISCUS

A, E, H

 

3934

PISUM SATIVUM

A, E, H

 

3935

PLACENTA

H

Only for use as an active homoeopathic ingredient.

 

3936

PLANTAGO AFRA

A, E, H

When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:

- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

 

3937

PLANTAGO ARENARIA

A, H

When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:

- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

 

3938

PLANTAGO ASIATICA

A, H

When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:

- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

 

3939

PLANTAGO LANCEOLATA

A, E, H

The medicine requires the following warning statement on the medicine label:

- (CHILD5) 'Use in children under 3 years is not recommended’

When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:

- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

 

3940

PLANTAGO MAJOR

A, E, H

When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:

- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

 

3941

PLANTAGO OVATA

A, H

When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:

- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

 

3942

PLANTAGO SEED DRY

A, H

When a dose for children is stated and the plant part is flower, seed or pollen, the following warning statement is required on the label:

- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

 

3943

PLATANUS OCCIDENTALIS

A, E, H

 

3944

PLATANUS RACEMOSA

A, H

 

3945

PLATANUS × HISPANICA

A, H

 

3946

PLATYCODON GRANDIFLORUS

A, E, H

 

3947

PLECTRANTHUS BARBATUS

A, E, H

 

3948

PLICATONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3949

PLUM

E

 

3950

PLUMBAGO EUROPAEA

A, H

 

3951

PLUMERIA ALBA

A, E, H

 

3952

PLUMERIA RUBRA

A, E, H

 

3953

POA NEMORALIS

A, H

 

3954

POA PRATENSIS

A, H

 

3955

PODOPHYLLUM PELTATUM

A, H

Podophyllin and podophyllotoxin are mandatory components of Podophyllum peltatum.

The concentration of podophyllin in the medicine must be no more than 1 mg/kg or 1 mg/L or 0.0001%.

The concentration of podophyllotoxin in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%.

 

3956

POGOSTEMON CABLIN

A, E, H

 

3957

POLACRILIN

E

 

3958

POLACRILIN POTASSIUM

E

 

3959

POLAPREZINC

A

Only for use in oral medicines.

Zinc is a mandatory component of Polaprezinc.

The maximum recommended daily dose must be no more than 34 milligrams of zinc sourced from polaprezinc.

When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc.

When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label:

- (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period' (or words to that effect).

 

3960

POLIGLUSAM

A, E

The average molecular mass of poliglusam must be greater than 2 kilodaltons.

When for internal use:

(a) the maximum recommended daily dose of the medicine must not provide more than 1750 milligrams poliglusam; and

(b) the following warning statement is required on the medicine label:

- (CHITO) 'Poliglusam should be taken at least one hour after any other medication as it may reduce the effect of other medication' (or words to that effect).

When for internal use and the dosage form is a powdered preparation, the following warning statement is required on the medicine label:

- (DNTPOW) 'Do not take powder alone. Mix with food or fluid'.

When used as an excipient, only for use in topical medicines for dermal application.

 

3961

POLIGLUSAM DERIVED FROM ASPERGILLUS NIGER

A, E

When for oral use:

(a) the maximum recommended daily dose of the medicine must not provide more than 2000 mg of Poliglusam derived from Aspergillus niger;

(b) the following warning statement (or words to the same effect) is required on the medicine label:

- (CHITO) 'Poliglusam should be taken at least one hour after any other medication as it may reduce the effect of other medication.'; and

(c) if the medicine is a powdered dosage form, the following warning statement is also required on the medicine label:

- (DNTPOW) 'Do not take powder alone. Mix with food or fluid.'

When used as an excipient, Poliglusam derived from Aspergillus niger is only permitted for use in topical medicines for dermal application.

 

3962

POLLACK-LIVER OIL

A, E

Colecalciferol and Vitamin A are mandatory components of Pollack-liver oil.

When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.

When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.

When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:

- (VITA2) ‘WARNING: If you are pregnant - or considering becoming pregnant - do not take vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA4) ‘WARNING - When taken in excess of 3000 micrograms retinol equivalents - Vitamin A can cause birth defects.’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA3) ‘The recommended daily amount of Vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.’

When for internal use, the maximum recommended daily dose must be no more than 25 micrograms of Vitamin D.

 

3963

POLLEN

E

The medicine requires the following warning statement on the medicine label:

- (POLLEN) 'This medicine can cause severe allergic reactions' (or words to that effect).

 

3964

POLOXAMER

E

Only for use in topical medicines for dermal application.

 

3965

POLOXAMINE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3966

POLY C10-30 ALKYL ACRYLATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

3967

POLYACRYLAMIDE

E

Only for use in topical medicines for dermal application.

Acrylamide is a mandatory component of Polyacrylamide.

The concentration of Acrylamide in the medicine must be no more than 0.01%.

 

3968

POLYACRYLATE CROSSPOLYMER-6

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2%.

 

3969

POLYACRYLATE-1 CROSSPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.4%.

 

3970

POLYACRYLIC ACID

E

 

3971

POLYAMINO SUGAR CONDENSATE

E

Only for use in topical medicines for dermal application.

 

3972

POLYAMINOPROPYL BIGUANIDE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.3%.

 

3973

POLYBUTADIENE

E

Only for use as part of an adhesive in topical medicines for dermal application.

 

3974

POLYBUTENE

E

Only for use in topical medicines for dermal application.

 

3975

POLYBUTYLENE GLYCOL/PPG-9/1 COPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

3976

POLYCAPROLACTONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

3977

POLYDECENE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 6%.

 

3978

POLYDEXTROSE

E

 

3979

POLYDIETHYLSILOXANE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 5%.

 

3980

POLYDIMETHYL SILOXANE

E

Permitted for use only in combination with other permitted ingredients as a printing ink.

If used in a printing ink the total printing ink concentration in a medicine must be no more than 0.1%

 

3981

POLYESTER-10

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.5%.

 

3982

POLYESTER-25

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 10%.

 

3983

POLYESTER-7

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

3984

POLYESTER-8

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration of Polyester-8 must be no more than 5%.

 

3985

POLYETHYLENE

E

 

3986

POLYGALA CHINENSIS

A, H

 

3987

POLYGALA SENEGA

A, E, H

Except when used in a medicine containing only homoeopathic preparations, a child resistant closure and restricted flow insert must be fitted onto the container.

 

3988

POLYGALA SIBIRICA

A, E, H

Only for use when the plant part is root or root bark.

 

3989

POLYGALA TENUIFOLIA

A

Only for use when the plant part is root or root bark.

 

3990

POLYGLYCERYL-10 PENTASTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.5%.

 

3991

POLYGLYCERYL-2 CAPRATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use on damaged skin or in the eye.

The concentration in the medicine must not be more than 0.5%.

 

3992

POLYGLYCERYL-2 DIISOSTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 3.0%.

 

3993

POLYGLYCERYL-2 DIPOLYHYDROXYSTEARATE

E

Only for use in topical medicines for dermal application. 

The concentration in the medicine must be no more than 5%.

 

3994

POLYGLYCERYL-2 DISTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 3%.

 

3995

POLYGLYCERYL-2 ISOSTEARATE

E

Polyglyceryl-2 isostearate must:

(a) Only be used in topical medicines for dermal application; and

(b) Not be included in medicines intended for use on broken skin or in the eye.

The concentration in the medicine must be no more than 2.5%.

 

3996

POLYGLYCERYL-2 TRIISOSTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

When the concentration of polyglyceryl-2 triisostearate is greater than 3%, the medicine must not be intended for use on damaged skin.

The concentration in the medicine must not be more than 5%.

 

3997

POLYGLYCERYL-2-PEG-4 STEARATE

E

Only for use in topical medicines for dermal application.

 

3998

POLYGLYCERYL-3 BEESWAX

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.5%.

 

3999

POLYGLYCERYL-3 DIISOSTEARATE

E

Only for use in topical medicines for dermal application.

 

4000

POLYGLYCERYL-3 DISTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

4001

POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 6%.

 

4002

POLYGLYCERYL-3 POLYDIMETHYLSILOXYETHYL DIMETHICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5.5%.

 

4003

POLYGLYCERYL-3 POLYRICINOLEATE

E

 

4004

POLYGLYCERYL-3 STEARATE/ISOSTEARATE/DIMER DILINOLEATE CROSSPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 5%.

 

4005

POLYGLYCERYL-4 DIISOSTEARATE/POLYHYDROXYSTEARATE/SEBACATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 3%.

 

4006

POLYGLYCERYL-4 ISOSTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4007

POLYGLYCERYL-4 OLEATE

E

Only for use in topical medicines for dermal application.

 

4008

POLYGLYCERYL-6 POLYRICINOLEATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4009

POLYGLYCERYL-6 RICINOLEATE

E

Only for use in topical medicines for dermal application.

 

4010

POLYGONATUM MULTIFLORUM

A, H

 

4011

POLYGONATUM OFFICINALE

A, H

 

4012

POLYGONATUM SIBIRICUM

A, E, H

 

4013

POLYGONUM AVICULARE

A, E, H

When used as an excipient, the medicine is only for use in topical medicines for dermal application and not to be included in medicines intended for use on damaged skin or in the eye.

When used as an excipient, the concentration in the medicine must be no more than 0.16%.

 

4014

POLYGONUM BISTORTA

A, H

 

4015

POLYGONUM ODORATUM

A, H

 

4016

POLYHYDROXYSTEARIC ACID

E

Only for use in topical medicines for dermal application.

 

4017

POLYISOBUTYLENE

E

Only for use when the dosage form is 'chewing gum'.

Must comply with:

a) the Polyisobutylene monograph in the Food Chemicals Codex published by the United States Pharmacopeial Convention, as in force or existing from time to time; and b) the requirements for residual solvents and catalysts in the British Pharmacopoeia or the United States Pharmacopeia National Formulary, as in force or existing from time to time.

 

4018

POLYISOPRENE

E

Only for use in topical medicines for dermal application.

 

4019

POLYLIMONENE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4020

POLYMETHACRYLIC ACID

E

 

4021

POLYMETHYL METHACRYLATE

E

Methyl methacrylate is a mandatory component of polymethyl methacrylate.

Only for use in topical medicines for dermal application.

The total concentration of methyl methacrylate as residual monomer in the medicine must not be more than 1%.

 

4022

POLYMETHYLSILSESQUIOXANE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 3%.

 

4023

POLYPORUS UMBELLATUS

A, H

 

4024

POLYPROPYLENE

E

Only for use in topical medicines for dermal application.

 

4025

POLYPROPYLENE GLYCOL

E

Permitted for use only in combination with other permitted ingredients as part of a flavour or fragrance proprietary excipient formulation.

When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%.

When used in a fragrance, the total fragrance proprietary excipient formulation in a medicine must be no more than 1%.

 

4026

POLYQUATERNIUM-10

E

Only for use in topical medicines for dermal application.

 

4027

POLYQUATERNIUM-11

E

Only for use in topical medicines for dermal application.

 

4028

POLYQUATERNIUM-22

E

Only for use in wash-off topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2%.

 

4029

POLYQUATERNIUM-24

E

Only for use in topical medicines for dermal application.

 

4030

POLYQUATERNIUM-28

E

Only for use in topical medicines for dermal application.

 

4031

POLYQUATERNIUM-37

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2.5%.

 

4032

POLYQUATERNIUM-4

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 0.4%.

 

4033

POLYQUATERNIUM-44

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.3%.

 

4034

POLYQUATERNIUM-51

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4035

POLYQUATERNIUM-7

E

Only for use in topical medicines for dermal application.

 

4036

POLYSILICONE-11

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2.1%

 

4037

POLYSILICONE-14

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration of Polysilicone-14 must be no more than 1%.

 

4038

POLYSILICONE-15

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 10%.

When used in primary sunscreen products, the following warning statements are required on the label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

4039

POLYSILICONE-2

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.13%.

 

4040

POLYSORBATE 20

E

 

4041

POLYSORBATE 40

E

 

4042

POLYSORBATE 60

E

 

4043

POLYSORBATE 65

E

 

4044

POLYSORBATE 80

E

 

4045

POLYSORBATE 85

E

Only for use in topical medicines for dermal application.

 

4046

POLYSTYRENE

E

Only for use as part of an adhesive in topical medicines for dermal application.

 

4047

POLYTEF

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

4048

POLYURETHANE-34

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2% in spray applications and 6% in non-spray applications.

 

4049

POLYURETHANE-62

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 5%.

 

4050

POLYVINYL ACETATE

E

Only permitted for use in medicines that are for oral routes of administration.

 

4051

POLYVINYL ACETATE PHTHALATE

E

 

4052

POLYVINYL ALCOHOL

E

 

4053

POLYVINYL CHLORIDE

E

Only for use in topical medicines for dermal application.

 

4054

POMEGRANATE

E

 

4055

PONCEAU SX

E

Permitted for use only as a colour for topical use.

 

4056

PONCIRUS TRIFOLIATA

A, H

When used internally, oxedrine is a mandatory component of Poncirus trifoliata.

The quantity of Oxedrine in the maximum recommended daily dose must be no more than 30 mg.

 

4057

PONGAMOL

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4058

PONTEDERIA CRASSIPES

A, H

 

4059

POPPY SEED

E, H

 

4060

POPPY SEED OIL

E, H

 

4061

POPULUS ALBA

A, H

 

4062

POPULUS BALSAMIIFERA

A, E, H

 

4063

POPULUS CANDICANS

A, H

 

4064

POPULUS DELTOIDES

A, H

 

4065

POPULUS NIGRA

A, H

 

4066

POPULUS TREMULA

A, H

 

4067

POPULUS TREMULOIDES

A, H

 

4068

PORCINE

H

Only for use as an active homoeopathic ingredient. 

 

4069

PORPHYRIDIUM PURPUREUM EXTRACT

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

4070

PORTULACA OLERACEA

A, E, H

 

4071

POTABLE WATER

E

 

4072

POTASSIUM ACETATE

E

 

4073

POTASSIUM ARSENITE

H

Only for use as an active homoeopathic ingredient.

 

4074

POTASSIUM ASCORBATE

A, E, H

When for oral or sublingual use, potassium is a mandatory component of potassium ascorbate.

 

4075

POTASSIUM ASCORBATE DIHYDRATE

A, E, H

When for oral or sublingual use, potassium is a mandatory component of potassium ascorbate dihydrate.

 

4076

POTASSIUM ASCORBYL TOCOPHERYL PHOSPHATE

E

Only for use in topical medicines for dermal application.

 

4077

POTASSIUM ASPARTATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium aspartate.

 

4078

POTASSIUM ASPARTATE DIHYDRATE

A, E, H

If used as an active ingredient and the preparation is intended as a mineral supplementation, potassium is a mandatory component of Potassium aspartate dihydrate. The percentage of potassium from potassium aspartate dihydrate should be calculated based on the molecular weight of potassium aspartate dihydrate.

 

4079

POTASSIUM ASPARTATE MONOHYDRATE

A, E

If used as an active ingredient and the preparation is intended as a mineral supplementation, potassium is a mandatory component of Potassium aspartate monohydrate. The percentage of potassium from potassium aspartate monohydrate should be calculated based on the molecular weight of potassium aspartate monohydrate.

 

4080

POTASSIUM BICARBONATE

E

 

4081

POTASSIUM BROMIDE

H

Only for use as an active homoeopathic ingredient.

The total concentration of potassium bromide in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.

 

4082

POTASSIUM CARBONATE

E, H

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

 

4083

POTASSIUM CETYL PHOSPHATE

E

Only for use in topical medicines for dermal application.

 

4084

POTASSIUM CHLORIDE

A, E, H

When for oral use:

(a) potassium is a mandatory component of potassium chloride;

(b) the medicine requires the following warning statement on the medicine label:

- (POTAS1) 'If you have kidney disease or are taking heart or blood pressure medicines - consult your doctor or pharmacist before use. Keep out of reach of children.'; and

(c) except when the medicine is for use as oral rehydration therapy, the amount of potassium chloride per dosage unit must not be more than 550 mg.

Medicines containing potassium chloride for use as oral rehydration therapy, are subject to the following conditions:

(a) the medicine complies with the requirements specified in the British Pharmacopoeia, as in force or existing from time to time, for Oral Rehydration Salts;

(b) the sodium, potassium and glucose content, and total osmolarity of the solution after it has been prepared according to the instructions on the packet are consistent with the criteria specified by the World Health Organisation (WHO) and the United Nations Children's Fund (UNICEF) in the document 'Expert consultation on oral rehydration salts formulation' 18 July 2001; and

(c) the following warning statements are required on the medicine label:

- (UOAD) 'Use only as directed'

- (DIAR3) 'If diarrhoea persists, seek medical advice.'

When for dental use, the concentration of potassium chloride in the medicine must not be more than 3.75%.

 

4085

POTASSIUM CITRATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium citrate.

 

4086

POTASSIUM COCOYL HYDROLYSED COLLAGEN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 10%.

 

4087

POTASSIUM COCOYL HYDROLYSED SOY PROTEIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.15%.

 

4088

POTASSIUM DICHROMATE

H

Only for use as an active homoeopathic ingredient.

 

4089

POTASSIUM GLUCONATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium gluconate.

 

4090

POTASSIUM GLYCEROPHOSPHATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium glycerophosphate.

 

4091

POTASSIUM HYDROXIDE

E

The concentration in the medicine must be no more than 5%.

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

 

4092

POTASSIUM HYDROXYCITRATE

A, H

 

4093

POTASSIUM IODATE

A, H

Iodine is a mandatory component of potassium iodate.

The percentage of iodine from potassium iodate should be calculated based on the molecular weight of potassium iodate.

When for use in adults, the medicine must contain a daily dose of no more than 505 micrograms of potassium iodate.

When for use in children aged 1-3 years, the medicine must contain a daily dose of no more than 337 micrograms of potassium iodate.

 

4094

POTASSIUM IODIDE

A, E, H

Iodine is a mandatory component of potassium iodide.

The percentage of iodine from potassium iodide should be calculated based on the molecular weight of potassium iodide.

When for internal use, the maximum recommended daily dose of the medicine must contain less than 300 micrograms of iodine.

When for external use, the concentration of iodine in the medicine (excluding salt derivatives or iodophors) must not exceed 2.5%.

 

4095

POTASSIUM METABISULFITE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4096

POTASSIUM METAPHOSPHATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

4097

POTASSIUM NITRATE

A, H

Only for dental use.

The concentration in the medicine must be no more than 5%.

 

4098

POTASSIUM OROTATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium orotate.

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

 

4099

POTASSIUM PYROPHOSPHATE

E

Only for oral application, dental or topical use.

Not to be included in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 3%.

 

4100

POTASSIUM SORBATE

E

 

4101

POTASSIUM STANNATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4102

POTASSIUM STEARATE

E

Only for use in topical medicines for dermal application.

 

4103

POTASSIUM SULFATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium sulfate.

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

 

4104

POTATO STARCH

E

 

4105

POTENTILLA ANSERINA

A, H

 

4106

POTENTILLA CHINENSIS

A, H

 

4107

POTENTILLA DISCOLOR

A, H

 

4108

POTENTILLA ERECTA

A, E, H

 

4109

POTENTILLA REPTANS

A, H

 

4110

POTERIUM OFFICINALE

A, E, H

 

4111

POTERIUM SANGUISORBA

A, H

 

4112

POVIDONE

E

 

4113

POWDERED CELLULOSE

E

 

4114

PPG-1-PEG-9 LAURYL GLYCOL ETHER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4115

PPG-12/SMDI COPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

4116

PPG-15 STEARYL ETHER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4%.

 

4117

PPG-15 STEARYL ETHER BENZOATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.4%.

 

4118

PPG-17/IPDI/DMPA COPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin.

The concentration of PPG-17/IPDI/DMPA Copolymer in the medicine must be no more than 10%.

 

4119

PPG-2 LANOLIN ALCOHOL ETHER

E

Only for use in topical medicines for dermal application.

 

4120

PPG-2 MYRISTYL ETHER PROPIONATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4121

PPG-20 LANOLIN ALCOHOL ETHER

E

Only for use in topical medicines for dermal application.

 

4122

PPG-20 METHYL GLUCOSE ETHER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

4123

PPG-20 METHYL GLUCOSE ETHER DISTEARATE

E

Only for use in topical medicines for dermal application.

 

4124

PPG-3 HYDROGENATED CASTOR OIL

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. 

The concentration in the medicine must be no more than 6%.

 

4125

PPG-3 MYRISTYL ETHER

E

Only for use in topical medicines for dermal application.

 

4126

PPG-5-CETETH-20

E

Only for use in topical medicines for dermal application.

 

4127

PPG-5-LAUROMACROGOL 250

E

Only for use in topical medicines for dermal application.

 

4128

PRALINE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4129

PREGELATINISED MAIZE STARCH

E

 

4130

PREGELATINISED POTATO STARCH

E

 

4131

PREGELATINISED RICE STARCH

E

 

4132

PREGELATINISED STARCH

E

 

4133

PREGELATINISED WHEAT STARCH

E

When the route of administration is other than topical or mucosal, gluten is a mandatory component of pregelatinised wheat starch.

 

4134

PRENYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4135

PRICKLY ASH BARK DRY

A, H

 

4136

PRICKLY ASH BARK POWDER

A, H

 

4137

PRIMULA VERIS

A, E, H

 

4138

PRIMULA VULGARIS

A, E, H

 

4139

PRINSEPIA UNIFLORA

A, H

 

4140

PROBOSCIDEA PARVIFLORA

A, H

 

4141

PROGESTERONE

H

Only for use as an active homoeopathic ingredient.

The total concentration of progesterone in the medicine must not be more than 1 mg/kg or 1 mg/L or 0.0001%.

 

4142

PROLINE

A, E

 

4143

PROPAN-1-OL

E

Only for use in:

- topical medicines for dermal application; or

- in combination with other permitted ingredients as a flavour proprietary excipient formulation.

The concentration of propan-1-ol in the medicine must not be more than 18%.

When used in medicines in combination with other permitted ingredients as a flavour proprietary excipient formulation, the total flavour proprietary excipient formulation in a medicine must not be more than 5%.

 

4144

PROPANE

E

Only for use as an excipient propellant ingredient.

 

4145

PROPANEDIOL

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 10%.

 

4146

PROPENYL GUAETHOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4147

PROPIONALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4148

PROPIONIC ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4149

PROPIONYLLEVOCARNITINE HYDROCHLORIDE

A, H

 

4150

PROPOLIS

A, E

Lead is a mandatory component of Propolis.

The concentration of lead in the medicine must be no more than 0.001%.

When used topically, the medicine requires the following warning statement on the medicine label:

-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'

When used for other than for topical, the medicine requires the following warning statement on the medicine label:

- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'

 

4151

PROPOLIS BALSAM

A, E

Lead is a mandatory component of Propolis balsam.

The concentration of lead in the medicine must be no more than 0.001%.

When used topically, the medicine requires the following warning statement on the medicine label:

-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'

When used for other than for topical, the medicine requires the following warning statement on the medicine label:

- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'

 

4152

PROPOLIS DRY EXTRACT

A, E

Lead is a mandatory component of Propolis dry extract.

The concentration of lead in the medicine must be no more than 0.001%.

When used topically, the medicine requires the following warning statement on the medicine label:

-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'

When used for other than for topical, the medicine requires the following warning statement on the medicine label:

- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'

 

4153

PROPOLIS LIQUID EXTRACT

A, E

Lead is a mandatory component of Propolis liquid extract.

The concentration of lead in the medicine must be no more than 0.001%.

When used topically, the medicine requires the following warning statement on the medicine label:

-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'

When used for other than for topical, the medicine requires the following warning statement on the medicine label:

- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'

 

4154

PROPOLIS RESIN

A, E

Lead is a mandatory component of propolis resin.

The concentration of lead in the medicine must be no more than 0.001%.

When used topically, the medicine requires the following warning statement on the medicine label:

-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'

When used for other than for topical, the medicine requires the following warning statement on the medicine label:

- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'

 

4155

PROPOLIS TINCTURE

A, E

Lead is a mandatory component of Propolis tincture.

The concentration of lead in the medicine must be no more than 0.001%.

When used topically, the medicine requires the following warning statement on the medicine label:

-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'

When used for other than for topical, the medicine requires the following warning statement on the medicine label:

- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'

 

4156

PROPYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4157

PROPYL CAPROATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4158

PROPYL GALLATE

E

 

4159

PROPYL HYDROXYBENZOATE

E

 

4160

PROPYLENE CARBONATE

E

Only for use in topical medicines for dermal application.

 

4161

PROPYLENE GLYCOL

E

 

4162

PROPYLENE GLYCOL ALGINATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4163

PROPYLENE GLYCOL DIBENZOATE

E

Only for use in topical medicines for dermal application only and not to be used in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 20%.

 

4164

PROPYLENE GLYCOL DIDECANOATE

E

Only for use in topical medicines for dermal application only and not to be used in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4165

PROPYLENE GLYCOL DIOCTANOATE

E

Only for use in topical medicines for dermal application.

 

4166

PROPYLENE GLYCOL DIOCTANOATE/DIDECANOATE

E

Only for use in topical medicines for dermal application.

 

4167

PROPYLENE GLYCOL DIPELARGONATE

E

Only for use in topical medicines for dermal application.

 

4168

PROPYLENE GLYCOL ISOCETETH-3 ACETATE

E

Only for use in topical medicines for dermal application only and not to be used in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4169

PROPYLENE GLYCOL ISOSTEARATE

E

Only for use in topical medicines for dermal application.

 

4170

PROPYLENE GLYCOL MONOLAURATE

E

Only for use in topical medicines for dermal application.

 

4171

PROPYLENE GLYCOL MONOSTEARATE

E

Only for use in topical medicines for dermal application.

 

4172

PROPYLENE GLYCOL MYRISTYL ETHER ACETATE

E

Only for use in topical medicines for dermal application.

 

4173

PROSOPIS JULIFLORA

A, H

 

4174

PROTEASE

A

Must be derived from Aspergillus oryzae or Aspergillus niger.

 

4175

PROTEIN HYDROLYSATE

E

 

4176

PRUNE JUICE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4177

PRUNE JUICE CONCENTRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4178

PRUNELLA VULGARIS

A, H

 

4179

PRUNUS AFRICANA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus africana.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4180

PRUNUS ARMENIACA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus armeniaca and must be declared in the application.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4181

PRUNUS AVIUM

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus avium.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4182

PRUNUS CERASIFERA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus cerasifera.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4183

PRUNUS CERASUS

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus cerasus.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4184

PRUNUS DOMESTICA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus domestica.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4185

PRUNUS DULCIS

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus dulcis when the plant part is seed.

When the plant part is seed, the maximum recommended daily dose must be no more than the equivalent of 1mg of the dry seed.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4186

PRUNUS HUMILIS

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus humilis.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4187

PRUNUS JAPONICA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus japonica.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4188

PRUNUS LAUROCERASUS

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus laurocerasus.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4189

PRUNUS MUME

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus mume.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4190

PRUNUS PERSICA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus persica.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4191

PRUNUS SALICINA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus salicina.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4192

PRUNUS SEROTINA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus serotina.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4193

PRUNUS SPINOSA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus spinosa.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4194

PRUSSIAN BLUE

E

Permitted for use only as a colour for topical use.

 

4195

PSEUDOCYDONIA SINENSIS

A, H

 

4196

PSEUDOSTELLARIA HETEROPHYLLA

A, E, H

 

4197

PSEUDOTSUGA MENZIESII

A, H

 

4198

PSEUDOWINTERA COLORATA

A, H

Only for use when the plant part is leaf.

 

4199

PSIDIUM GUAJAVA

A, E, H

 

4200

PSORINUM

H

Only for use as an active homoeopathic ingredient. 

 

4201

PSYLLIUM HUSK DRY

A, H

When a dose for children is stated, the following warning statement is required on the label:

- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

 

4202

PSYLLIUM HUSK POWDER

A, E, H

When a dose for children is stated, the following warning statement is required on the label:

- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

 

4203

PSYLLIUM SEED DRY

A, E, H

When a dose for children is stated the following warning statement is required on the label:

- (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

 

4204

PTELEA TRIFOLIATA

A, H

 

4205

PTEROCARPUS MARSUPIUM

A, H

 

4206

PTEROCARPUS SANTALINUS

A, E, H

 

4207

PUERARIA LOBATA

A, E, H

 

4208

PUERARIA MONTANA VAR. LOBATA

A, E, H

 

4209

PULLULAN

E

 

4210

PUMICE

E

 

4211

PUMPKIN

E

 

4212

PUMPKIN SEED OIL

E, H

 

4213

PUNICA GRANATUM

A, E, H

 

4214

PURE BEE VENOM

H

Only for use as an active homoeopathic ingredient.

 

4215

PURIFIED HONEY

A, E

When the route of administration is oral, the following warning statement is required on the medicine label:

- (BABY2) 'Not suitable for infants under the age of twelve months' (or words to that effect).

 

4216

PURIFIED SILICEOUS EARTH

E, H

 

4217

PURIFIED TALC

E

 

4218

PURIFIED WATER

E

 

4219

PVM/MA COPOLYMER

E

 

4220

PVM/MA DECADIENE CROSSPOLYMER

E

Only for use in topical medicines for dermal application.

 

4221

PVP/EICOSENE COPOLYMER

E

Only for use in topical medicines for dermal application.

 

4222

PVP/HEXADECENE COPOLYMER

E

Only for use in topical medicines for dermal application.

 

4223

PYRETHRINS

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 10%.

The medicine requires the following warning statement on the medicine label:

- (PYRTH3) 'Contains pyrethrins [insert quantity]' (or words to that effect).

 

4224

PYRIDOXAL 5-PHOSPHATE

A, E

Pyridoxine is a mandatory component of pyridoxal 5-phosphate.

The percentage of pyridoxine from pyridoxal 5-phosphate should be calculated based on the molecular weight of pyridoxal 5-phosphate.

The maximum recommended daily dose of the medicine must not provide more than:

(i) 15 mg of pyridoxine for children aged between 1 and 3 years (inclusive);

(ii) 20 mg of pyridoxine for children aged between 4 and 8 years (inclusive);

(iii) 30 mg of pyridoxine for children aged between 9 and 13 years (inclusive);

(iv) 40 mg of pyridoxine for individuals aged 14 and 18 years (inclusive); and

(v) 100 mg of pyridoxine for individuals aged 19 years and older.

If the maximum recommended daily dose of the medicine provides more than 10 mg of pyridoxine, the following warning statement is required on the medicine label:

- (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].

 

4225

PYRIDOXAL 5-PHOSPHATE MONOHYDRATE

A

Pyridoxine is a mandatory component of pyridoxal 5-phosphate monohydrate.

The percentage of pyridoxine from pyridoxal 5-phosphate monohydrate should be calculated based on the molecular weight of pyridoxal 5-phosphate monohydrate.

The maximum recommended daily dose of the medicine must not provide more than:

(i) 15 mg of pyridoxine for children aged between 1 and 3 years (inclusive);

(ii) 20 mg of pyridoxine for children aged between 4 and 8 years (inclusive);

(iii) 30 mg of pyridoxine for children aged between 9 and 13 years (inclusive);

(iv) 40 mg of pyridoxine for individuals aged 14 and 18 years (inclusive); and

(v) 100 mg of pyridoxine for individuals aged 19 years and older.

If the maximum recommended daily dose of the medicine provides more than 10 mg of pyridoxine, the following warning statement is required on the medicine label:

- (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].'

 

4226

PYRIDOXINE HYDROCHLORIDE

A, E, H

When not used as an active homoeopathic ingredient, pyridoxine is a mandatory component of pyridoxine hydrochloride.

The percentage of pyridoxine from pyridoxine hydrochloride should be calculated based on the molecular weight of pyridoxine hydrochloride.

The maximum recommended daily dose of the medicine must not provide more than:

(i) 15 mg of pyridoxine for children aged between 1 and 3 years (inclusive);

(ii) 20 mg of pyridoxine for children aged between 4 and 8 years (inclusive);

(iii) 30 mg of pyridoxine for children aged between 9 and 13 years (inclusive);

(iv) 40 mg of pyridoxine for individuals aged 14 and 18 years (inclusive); and

(v) 100 mg of pyridoxine for individuals aged 19 years and older.

If the maximum recommended daily dose of the medicine provides more than 10 mg of pyridoxine, the following warning statement is required on the medicine label:

- (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].'

 

4227

PYROGLUTAMIC ACID

E

 

4228

PYROLA DECORATA

A, H

 

4229

PYROLIGNEOUS ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4230

PYRROSIA LINGUA

A, H

 

4231

PYRROSIA PETIOLOSA

A, H

 

4232

PYRROSIA SHEARERI

A, H

 

4233

PYRUS COMMUNIS

A, E, H

Beta-arbutin is a mandatory component of Pyrus communis.

When for oral use, the maximum recommended daily dose must not provide more than 500 mg of beta-arbutin.

When for dermal application exclusively to the face:

a) the concentration of beta-arbutin in the medicine must not be more than 7%; 

b) hydroquinone is a mandatory component; and

c) the concentration of hydroquinone must not be more than 10 mg/kg or 10 mg/L or 0.001%.

When for use other than oral or dermal application exclusively to the face, the concentration of beta-arbutin in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.

 

4234

PYRUS PYRIFOLIA

A, H

Beta-arbutin is a mandatory component of Pyrus pyrifolia.

When for oral use, the maximum recommended daily dose must not provide more than 500 mg of beta-arbutin.

When for dermal application exclusively to the face:

a) the concentration of beta-arbutin in the medicine must not be more than 7%;

b) hydroquinone is a mandatory component; and

c) the concentration of hydroquinone must not be more than 10 mg/kg or 10 mg/L or 0.001%.

When for use other than oral or dermal application exclusively to the face, the concentration of beta-arbutin in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.

 

4235

PYRUVIC ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4236

QUASSIA

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4237

QUASSIA AMARA

A, E, H

 

4238

QUASSIA WOOD JAMAICAN DRY

A, H

 

4239

QUASSIA WOOD JAMAICAN POWDER

A, H

 

4240

QUATERNIUM-15

E

Only for use in topical medicines for dermal application.

 

4241

QUATERNIUM-18 BENTONITE

E

Only for use in topical medicines for dermal application.

 

4242

QUATERNIUM-18 HECTORITE

E

Only for use in topical medicines for dermal application.

 

4243

QUATERNIUM-52

E

Only for use in wash-on/wash-off topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

Not be used in medicines in which N-nitroso compounds may be formed.

 

4244

QUATERNIUM-80

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2.5%.

 

4245

QUERCETIN

A

 

4246

QUERCETIN DIHYDRATE

A

 

4247

QUERCUS ACUTISSIMA

A, H

 

4248

QUERCUS ALBA

A, E, H

 

4249

QUERCUS PALUSTRIS

A, H

 

4250

QUERCUS ROBUR

A, H

 

4251

QUERCUS RUBRA

A, H

 

4252

QUERCUS VIRGINIANA

A, H

 

4253

QUILLAIA DRY

A, H

 

4254

QUILLAIA POWDER

A, E, H

 

4255

QUILLAJA SAPONARIA

A, H

 

4256

QUINCE

E

 

4257

QUININE ARSENITE

H

Only for use as an active homoeopathic ingredient.

Quinine is a mandatory component of Quinine arsenite.

The maximum recommended daily dose must be no more than 50 mg of quinine.

 

4258

QUININE SULFATE DIHYDRATE

H

Only for use as an active homoeopathic ingredient. 

Quinine is a mandatory component of quinine sulfate dihydrate. 

The maximum recommended daily dose must be no more than 50 mg of quinine.

 

4259

QUINOLINE YELLOW

E

Permitted for use only as a colour for oral and topical use.

 

4260

QUINOLINE YELLOW ALUMINIUM LAKE

E

Permitted for use only as a colour for oral and topical use.

 

4261

QUISQUALIS INDICA

A, H

 

4262

R-ALPHA LIPOIC ACID

A

 

4263

RACEMENTHOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4264

RACEMIC CAMPHOR

E, H

Only for use as an active homoeopathic or excipient ingredient.

In solid and semi solid preparations, the concentration of camphor must not be more than 12.5%.

In liquid preparations other than essential oils, the concentration of camphor must not be more than 2.5%.

In essential oil preparations, if the concentration of camphor is more than 2.5% but less than or equal to 10%, and the nominal capacity of the container is less than 25 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect);

- (NTAKEN) 'Not to be taken'; and

- (BABY4) ‘Do not apply to infants under 12 months of age except on the advice of a doctor or pharmacist’ (or words to that effect).

In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is less than 15 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect);

- (NTAKEN) 'Not to be taken'; and

- (BABY4) ‘Do not apply to infants under 12 months of age except on the advice of a doctor or pharmacist’ (or words to that effect).

In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, the medicine must have a restricted flow insert and child resistant closure fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect);

- (NTAKEN) 'Not to be taken'; and

- (BABY4) ‘Do not apply to infants under 12 months of age except on the advice of a doctor or pharmacist’ (or words to that effect).

If the concentration of camphor is more than 2.5%, the nominal capacity of the container must not be more than 25 millilitres.

 

4265

RADISH

E

 

4266

RAISIN JUICE CONCENTRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4267

RANUNCULUS BULBOSUS

A, H

 

4268

RANUNCULUS FICARIA

A, H

 

4269

RANUNCULUS TERNATUS

A, H

 

4270

RAPE SEED OIL

A, E, H

Allyl isothiocyanate is a mandatory component of rape seed oil when the plant part is seed.

The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.

 

4271

RAPHANUS SATIVUS

A, H

 

4272

RASPBERRY

E

 

4273

RASPBERRY BRANDY

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4274

RASPBERRY DISTILLATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4275

RASPBERRY FRUIT EXTRACT

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4276

RASPBERRY JUICE CONCENTRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4277

RAUWOLFIA SERPENTINA

A, H

The concentration of equivalent dry Rauwolfia serpentina in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%.

 

4278

RAUWOLFIA SERPENTINA DRY

A, H

The concentration of Rauwolfia Serpentina Dry in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%.

 

4279

RAUWOLFIA SERPENTINA POWDER

A, H

The concentration of Rauwolfia Serpentina Powder in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%.

 

4280

RED 27

E

Permitted for use only as a colour in medicines limited to topical and oral routes of administration.

The concentration in the medicine must be no more than 0.5%.

 

4281

RED 27 ALUMINIUM LAKE

E

Permitted for use only as a colour in medicines limited to topical and oral routes of administration.

The concentration in the medicine must be no more than 0.5%.

 

4282

RED ANT

H

Only for use as an active homoeopathic ingredient.

 

4283

RED CLOVER FLOWER DRY

A, H

 

4284

RED CLOVER FLOWER POWDER

A, H

 

4285

RED CORAL

H

Only for use as an active homoeopathic ingredient.

 

4286

RED DEER

A

 

4287

RED MERCURIC IODIDE

H

Only for use as an active homoeopathic ingredient.

 

4288

RED MERCURIC OXIDE

H

Only for use as an active homoeopathic ingredient.

 

4289

RED MERCURIC SULFIDE

H

Only for use as an active homoeopathic ingredient.

 

4290

REFINED BUGLOSSOIDES ARVENSIS SEED OIL

A

Only to be used in a medicine where Phytolove Pty Ltd (Client ID 80651), who applied to have the ingredient included in this Determination, is the sponsor of the medicine or has given written authorisation to the sponsor of a medicine to include the ingredient in the medicine. This paragraph ceases to be a requirement for this ingredient after 3 July 2025.

Stearidonic acid is a mandatory component of refined Buglossoides arvensis seed oil.

The route of administration for medicines that contain refined Buglossoides arvensis seed oil must be limited to oral.

The maximum recommended daily dose of the medicine must not provide more than 500 mg of stearidonic acid.

The following warning statement (or words to that effect) is required on the medicine label:

- (NTAKEN3) 'Not to be taken by children under 3 years old'.

 

 

4291

REHMANNIA GLUTINOSA

A, E, H

 

4292

REL-1-((1R,2S)-1,2,3,4,5,6,7,8-OCTAHYDRO-1,2,8,8-TETRAMETHYL-2-NAPHTHALENYL)-1-ETHANONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4293

RESORCINOL

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4294

RESORCINOL DIMETHYLETHER

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4295

RESVERATROL

A

Only permitted for use in medicines that are for oral routes of administration.

The maximum recommended daily dose of the medicine must not contain more than 150 milligrams of resveratrol.

The following warning statements are required on the medicine label:

- (RESVER) 'Resveratrol may affect the way some medicines work, including Warfarin. Consult your health professional before taking with other medicines (or words to that effect).';

- (PREGNT) ‘Not recommended for use by pregnant and lactating women’ (or words to that effect)’; and

- (CHILD2) ‘Not suitable for children’.

 

4296

RETINOL

A, E

Vitamin A is a mandatory component of retinol.

When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.

When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.

When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:

- (VITA2) ‘WARNING: If you are pregnant - or considering becoming pregnant - do not take Vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA4) ‘WARNING - When taken in excess of 3000 micrograms retinol equivalents - Vitamin A can cause birth defects.’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA3) ‘The recommended daily amount of Vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.’

 

4297

RETINOL ACETATE

A, E

Vitamin A is a mandatory component of retinol acetate.

When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.

When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.

When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:

- (VITA2) ‘WARNING: If you are pregnant - or considering becoming pregnant - do not take Vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA4) ‘WARNING - When taken in excess of 3000 micrograms retinol equivalents - Vitamin A can cause birth defects.’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA3) ‘The recommended daily amount of Vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.’

 

4298

RETINOL PALMITATE

A, E

Vitamin A is a mandatory component of retinol palmitate.

When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.

When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.

When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:

- (VITA2) ‘WARNING: If you are pregnant - or considering becoming pregnant - do not take Vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA4) ‘WARNING - When taken in excess of 3000 micrograms retinol equivalents - Vitamin A can cause birth defects.’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA3) ‘The recommended daily amount of Vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.’

 

4299

REYNOUTRIA JAPONICA

A, E, H

When used as an excipient, only for use in topical medicines for dermal application.

 

4300

RHAMNOSE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4301

RHAMNUS CATHARTICA

A, H

When the route of administration is oral, Hydroxyanthracene derivatives is a mandatory component of Rhamnus cathartica.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4302

RHAMNUS FRANGULA

A, H

Glucofrangulins calculated as glucofrangulin A is a mandatory component of Rhamnus frangula.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4303

RHATANY ROOT DRY

A, H

 

4304

RHATANY ROOT POWDER

A, H

 

4305

RHEUM OFFICINALE

A, E, H

The plant part must not be leaf.

When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of Rheum officinale.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4306

RHEUM PALMATUM

A, E, H

The plant part must not be leaf.

When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of Rheum palmatum.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) ‘Use in children under 12 years is not recommended’;

- (LAX2) ‘Prolonged use may cause serious bowel problems’; and

- (LAX3) ‘Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) ‘Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) ‘This product contains [name of the herb(s) or the chemical component(s)]’; and

- (LAX4) ‘This product may have laxative effect’.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) ‘Use in children under 12 years is not recommended’;

- (LAX1) ‘Drink plenty of water' (or words to that effect); and

- (LAX2) ‘Prolonged use may cause serious bowel problems’.

 

4307

RHEUM RHAPONTICUM

A, E, H

The plant part must not be leaf.

When the route of administration is oral, Hydroxyanthracene derivatives is a mandatory component of Rheum rhaponticum.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4308

RHEUM TANGUTICUM

A, H

The plant part must not be leaf.

When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of Rheum tanguticum.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4309

RHODAMINE B

E

Permitted for use only as a colour for topical use.

 

4310

RHODINOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4311

RHODINYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used as a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4312

RHODIOLA ROSEA

A

Only for use in oral medicines.

Only available for use when the plant preparation is dry root powder, dry root powder as an aqueous extract or dry root powder as a hydroethanolic extract with no more than 70% ethanol v/v.

 

4313

RHODODENDRON AUREUM

A, H

 

4314

RHODODENDRON FERRUGINEUM

A, H

Beta-arbutin is a mandatory component of Rhododendron ferrugineum.

When for oral use, the maximum recommended daily dose must not provide more than 500 mg of beta-arbutin.

When for dermal application exclusively to the face:

a) the concentration of beta-arbutin in the medicine must not be more than 7%;

b) hydroquinone is a mandatory component; and

c) the concentration of hydroquinone must not be more than 10 mg/kg or 10 mg/L or 0.001%.

When for use other than oral or dermal application exclusively to the face, the concentration of beta-arbutin in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.

 

4315

RHODODENDRON GROENLANDICUM

A, H

 

4316

RHODODENDRON MOLLE

A, H

The maximum recommended daily dose of the medicine must be no more than 1mg of the dry herbal material.

 

4317

RHUBARB

E, H

When the route of administration is oral, Hydroxyanthracene derivatives is a mandatory component of Rhubarb.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4318

RHUBARB ROOT DRY

A, H

When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of rhubarb root dry.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4319

RHUBARB ROOT POWDER

A, H

When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of rhubarb root powder.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4320

RHUS AROMATICA

A, E, H

 

4321

RHUS CHINENSIS

A, H

 

4322

RHUS GLABRA

A, E, H

 

4323

RHUS VENENATA

H

Only for use as an active homoeopathic ingredient.

 

4324

RIBES GROSSULARIA

A, E, H

 

4325

RIBES NIGRUM

A, E, H

 

4326

RIBOFLAVIN

A, E

 

4327

RIBOFLAVIN SODIUM PHOSPHATE

A, E

 

4328

RIBOFLAVIN TETRAACETATE

E

Only for use in topical medicines for dermal application.

 

4329

RIBOFLAVINE

A, E

 

4330

RIBOFLAVINE SODIUM PHOSPHATE

A, E

 

4331

RIBONUCLEIC ACID

E

Only for use in topical medicines for dermal application.

 

4332

RIBOSE

A

Only for use in oral medicines.

 

4333

RICE

E

 

4334

RICE BRAN

E

 

4335

RICE BRAN OIL

E

 

4336

RICE BRAN WAX

A, E, H

 

4337

RICE STARCH

E

 

4338

RICE VINEGAR

E

 

4339

RICE WINE

E

Ethanol is a mandatory component of rice wine.

 

4340

RICINOLEIC ACID

E

Only for use in topical medicines for dermal application.

 

4341

RICINUS COMMUNIS

A, H

Only for use when the plant part must be seed and the plant preparation is oil fixed.

 

4342

ROBINIA PSEUDOACACIA

A, E, H

When the herbal substance is derived from plant parts other than the leaf or flower, the maximum recommended daily dose of the medicine must be no more than 1mg of the dry herbal material.

 

4343

ROHDEA JAPONICA

A, H

The maximum recommended daily dose must be no more than the equivalent of 1mg of the dry herbal material.

 

4344

ROSA ARVENSIS

A, E, H

 

4345

ROSA CANINA

A, E, H

 

4346

ROSA CYMOSA

A, E, H

 

4347

ROSA EGLANTERIA

A, E, H

 

4348

ROSA GALLICA

A, E, H

 

4349

ROSA LAEVIGATA

A, E, H

 

4350

ROSA MULTIFLORA

A, E, H

 

4351

ROSA ROXBURGHII FRUIT EXTRACT

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.002%.

 

4352

ROSA RUGOSA

A, E, H

 

4353

ROSA VILLOSA

A, E, H

 

4354

ROSA X CENTIFOLIA

A, E, H

 

4355

ROSA X DAMASCENA

A, E, H

 

4356

ROSANA

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4357

ROSE ABSOLUTE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4358

ROSE FRUIT FRESH

A, E, H

 

4359

ROSE HIP

E

 

4360

ROSE OIL

A, E, H

 

4361

ROSE OXIDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4362

ROSEMARY OIL

A, E, H

Safrole is a mandatory component of Rosemary oil.

When for internal use then the concentration of safrole in the medicine must be no more than 0.1%.

When for topical use then the concentration of safrole in the medicine must be no more than 1%.

 

4363

ROSMARINUS OFFICINALIS

A, E, H

Camphor and cineole are mandatory components of Rosmarinus officinalis.

In solid and semi solid preparations, the concentration of camphor must be no more than 12.5%.

In liquid preparations other than essential oils or distillates, the concentration of camphor must be no more than 2.5%.

When the concentration of cineole in the preparation is more than 25%, the nominal capacity of the container must not be more than 25 millilitres.

In liquid preparations other than essential oils or distillates, when the concentration of cineole in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, the medicine must have a child resistant closure and restricted flow insert fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

In liquid preparations other than essential oils or distillates, when the concentration of cineole in the preparation is more than 25% and the nominal capacity of the container is no more than 15 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

If the concentration of camphor is more than 2.5%, the nominal capacity of the container must be no more than 25 millilitres.

 

4364

ROYAL JELLY

A, E

10-Hydroxy-2-decenoic acid is a mandatory component of Royal jelly.

The medicine requires the following warning statements on the medicine label:

- (CHILD2) 'Not suitable for children'

- (ROYJ) 'Not to be taken by asthma and allergy sufferers' in 3 mm type, prominent on front and 'This product contains royal jelly which has been reported to cause severe allergic reactions and in rare cases fatalities, especially in asthma and allergy sufferers'.

 

4365

ROYAL JELLY FRESH

A, E

10-Hydroxy-2-decenoic acid is a mandatory component of Royal jelly fresh.

The medicine requires the following warning statements on the medicine label:

- (CHILD2) 'Not suitable for children'

- (ROYJ) 'Not to be taken by asthma and allergy sufferers' in 3 mm type, prominent on front and 'This product contains royal jelly which has been reported to cause severe allergic reactions and in rare cases fatalities, especially in asthma and allergy sufferers'.

 

4366

ROYAL JELLY LYOPHILISED

A, E

10-Hydroxy-2-decenoic acid is a mandatory component of Royal jelly lyophilised.

The medicine requires the following warning statements on the medicine label:

- (CHILD2) 'Not suitable for children'

- (ROYJ) 'Not to be taken by asthma and allergy sufferers' in 3 mm type, prominent on front and 'This product contains royal jelly which has been reported to cause severe allergic reactions and in rare cases fatalities, especially in asthma and allergy sufferers'.

 

4367

RUBBER NATURAL

E

Only for use in topical medicines for dermal application.

 

4368

RUBIA CORDIFOLIA

A, H

 

4369

RUBIA TINCTORUM

A, H

 

4370

RUBUS CHINGII

A, H

 

4371

RUBUS CORCHORIFOLIUS

A, H

 

4372

RUBUS COREANUS

A, E, H

 

4373

RUBUS FRUTICOSUS

A, E, H

 

4374

RUBUS IDAEUS

A, E, H

 

4375

RUBUS OCCIDENTALIS

A, E, H

 

4376

RUBUS PARVIFOLIUS

A, H

 

4377

RUBUS ROSIFOLIUS

A, H

 

4378

RUDBECKIA HIRTA

A, H

 

4379

RUE OIL

A, H

 

4380

RUM

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4381

RUMEX ACETOSA

A, H

 

4382

RUMEX ACETOSELLA

A, H

 

4383

RUMEX CONGLOMERATUS

A, H

 

4384

RUMEX CRISPUS

A, E, H

 

4385

RUMEX PULCHER

A, H

 

4386

RUMEX SCUTATUS

A, H

 

4387

RUSCUS ACULEATUS

A, H

 

4388

RUTA GRAVEOLENS

A, E, H

 

4389

RUTOSIDE

A, E

 

4390

RYE

E

Gluten is a mandatory component of Rye when the route of administration is other than topical and mucosal.

 

4391

RYE BRAN

E

Gluten is a mandatory component of Rye bran when the route of administration is other than topical and mucosal.

 

4392

S-ISOPROPYL 3-METHYLTHIOCROTONATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4393

SABINENE

E

Sabinene must only be included in medicines when in combination with other permitted ingredients as a flavour proprietary excipient formulation.

The total concentration of flavour proprietary excipient formulations containing sabinene must not be more than 5% of the total medicine.

 

4394

SABINENE HYDRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4395

SACCHARIDE ISOMERATE

E

Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 3.66%.

 

4396

SACCHARIN

E

 

4397

SACCHARIN SODIUM

E

 

4398

SACCHAROMYCES CEREVISIAE

A, E

When for topical use, the concentration in the medicine must be no more than 1%.

 

4399

SACCHAROMYCES CEREVISIAE (BOULARDII)

A

 

4400

SACCHAROMYCES CEREVISIAE POLYSACCHARIDES

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4401

SACCHAROMYCES/ZINC FERMENT

E

Only for use in topical medicines for dermal application.

 

4402

SACCHARUM OFFICINARUM

A, E, H

 

4403

SAFFLOWER OIL

A, E, H

 

4404

SAFFRON

E

Permitted for use only as a colour for either topical use or with an oral route of administration.

 

4405

SAGE LEAF DRY

A, E, H

Thujone is a mandatory component of Sage leaf dry.

The concentration of thujone in the medicine must be no more than 4%.

 

4406

SAGE LEAF POWDER

A, H

Thujone is a mandatory component of Sage leaf powder.

The concentration of thujone in the medicine must be no more than 4%.

 

4407

SAGE OIL DALMATIAN

A

Thujone is a mandatory component of Sage oil dalmatian.

The concentration of thujone in the medicine must be no more than 4%.

When the concentration of Sage oil dalmatian in the medicine is more than 10% and the nominal capacity of the container is no more than 15 mL, a restricted flow insert and child resistant closure must be  fitted on the container and the medicine requires the following warning statements on the medicine label:

- (CHILD) ‘Keep out of reach of children’ (or word to that effect)

- (NTAKEN) ‘Not to be taken’

 

4408

SAGE OIL SPANISH

A, E, H

 

4409

SALICORNIA EUROPAEA EXTRACT

E

Only for use in topical medicines for dermal use and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.002%.

 

4410

SALICYLALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4411

SALICYLIC ACID

E, H

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 40%.

 

4412

SALIX ALBA

A, E, H

 

4413

SALIX DAPHNOIDES

A, H

 

4414

SALIX DISCOLOR

A, H

 

4415

SALIX FRAGILIS

A, H

 

4416

SALIX NIGRA

A, H

 

4417

SALIX PURPUREA

A, H

 

4418

SALSOLA KALI

A, H

 

4419

SALVIA CHINENSIS

A, H

 

4420

SALVIA FRUTICOSA

A, H

 

4421

SALVIA HISPANICA

A, E, H

 

4422

SALVIA LAVANDULAEFOLIA

A, H

 

4423

SALVIA MILTIORRHIZA

A, H

 

4424

SALVIA OFFICINALIS

A, E, H

Thujone is a mandatory component of Salvia officinalis.

The concentration of thujone in the medicine must be no more than 4%.

 

4425

SALVIA SCLAREA

A, E, H

 

4426

SAMBUCUS CANADENSIS

A, H

 

4427

SAMBUCUS EBULUS

A, H

 

4428

SAMBUCUS NIGRA

A, E, H

 

4429

SANDALWOOD OIL EAST INDIAN

A, E, H

 

4430

SANGUINARIA CANADENSIS

H

Only for use as an active homoeopathic ingredient.

The potency must be more than 4X.

 

4431

SANICULA EUROPAEA

A, H

 

4432

SANTALUM ALBUM

A, E, H

 

4433

SANTALUM SPICATUM

A, E, H

The route of administration must be topical or inhalation.

The plant preparation must be oil.

The plant part must be root or stem wood including heartwood.

 

4434

SAPINDUS MUKOROSSI

A, H

 

4435

SAPONARIA OFFICINALIS

A, H

 

4436

SAPOSHNIKOVIA DIVARICATA

A, H

 

4437

SARCOSINE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

4438

SARGASSUM FUSIFORME

A, H

Iodine is a mandatory component of Sargassum fusiforme.

Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less.

Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.

 

4439

SARGASSUM SILIQUASTRUM

A, H

Iodine is a mandatory component of Sargassum siliquastrum.

Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less.

Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.

 

4440

SASSAFRAS ALBIDUM

A, H

Safrole is a mandatory component of Sassafras albidum.

When for internal use then the concentration of safrole in the medicine must be no more than 0.1%.

When for topical use then the concentration of safrole in the medicine must be no more than 1%.

 

4441

SATUREIA HORTENSIS

A, H

 

4442

SATUREIA MONTANA

A, H

 

4443

SAUROPUS SPATULIFOLIUS

A, H

 

4444

SAURURUS CHINENSIS

A, H

 

4445

SAUSSUREA COSTUS

A, H

 

4446

SAVORY OIL SUMMER

A, H

 

4447

SAXIFRAGA GRANULATA

A, E, H

 

4448

SAXIFRAGA STOLONIFERA

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 0.0816%.

 

4449

SCAPHIUM SCAPHIGERUM

A, H

 

4450

SCHEFFLERA HEPTAPHYLLA

A, H

 

4451

SCHINOPSIS QUEBRACHO-COLORADO

A, H

 

4452

SCHINUS MOLLE

A, H

 

4453

SCHINUS MOLLE OIL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4454

SCHISANDRA CHINENSIS

A, E, H

 

4455

SCHIZONEPETA TENUIFOLIA

A, E, H

 

4456

SCHOENOCAULON OFFICINALE

A, H

The maximum recommended daily dose of the medicine must not contain more than the equivalent of 1 mg of the dry herbal material.

The concentration of total alkaloids of Schoenocaulon officinale in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.

 

4457

SCLAREOL

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4458

SCLAREOLIDE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4459

SCLERANTHUS ANNUUS

A, H

 

4460

SCLEROTIUM GUM

E

Only for use in topical medicines for dermal application.

 

4461

SCOPOLIA CARNIOLICA

A, H

The concentration of equivalent dry Scopolia carniolica in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%.

 

4462

SCROPHULARIA NINGPOENSIS

A, H

 

4463

SCROPHULARIA NODOSA

A, H

 

4464

SCURRULA PARASITICA VAR. GRACILIFLORA

A, H

 

4465

SCUTELLARIA BAICALENSIS

A, E, H

 

4466

SCUTELLARIA BARBATA

A, H

 

4467

SCUTELLARIA LATERIFLORA

A, E, H

 

4468

SEA WHIP EXTRACT

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.02%.

 

4469

SEC BUTYL 3-METHYLBUT-2-ENETHIOATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4470

SEC-BUTYL THIOISOVALERATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4471

SECALE CEREALE

A, H

Gluten is a mandatory component of Secale cereale when the plant part is seed and the route of administration is other than topical and mucosal.

 

4472

SEDUM ACRE

A, H

 

4473

SELAGINELLA TAMARISCINA

A, H

 

4474

SELENICEREUS GRANDIFLORUS

A, E, H

 

4475

SELENIUM

H

Only for use as an active homoeopathic ingredient.

Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses.

A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.'

 

4476

SELENOCYSTEINE

A

Selenium is a mandatory component of Selenocysteine for oral and sublingual use.

Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses.

 A daily dose of 150 mcg for adults of selenium from dietary supplements should not be exceeded.'

 

4477

SELENOMETHIONINE

A

Selenium is a mandatory component of Selenomethionine for oral and sublingual use.

Oral medicines must not contain more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.’

 

4478

SELF-EMULSIFYING GLYCERYL MONOSTEARATE

E

 

4479

SEMECARPUS ANACARDIUM

A, H

When the plant part is other than seed, the maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material.

 

4480

SEMOLINA

E

 

4481

SEMPERVIVUM TECTORUM

A, H

 

4482

SENEGA ROOT DRY

A, H

 

4483

SENEGA ROOT POWDER

A, H

 

4484

SENNA ALEXANDRINA

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna alexandrina.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4485

SENNA FRUIT ALEXANDRIAN DRY

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna fruit alexandrian dry.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4486

SENNA FRUIT ALEXANDRIAN POWDER

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna fruit alexandrian powder.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4487

SENNA FRUIT TINNEVELLY DRY

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna fruit tinnevelly dry.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4488

SENNA FRUIT TINNEVELLY POWDER

A, H

When for oral or sublingual, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna fruit tinnevelly powder.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4489

SENNA LEAF DRY

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna leaf dry.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]';

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4490

SENNA LEAF POWDER

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna Leaf Powder.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4491

SENNA OCCIDENTALIS

A, H

Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna occidentalis when the route of administration is oral administration.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' [or words to that effect].

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' [or words to that effect].

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended;

- (LAX1) 'Drink plenty of water' [or words to that effect]; and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4492

SENNA TORA

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna tora.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4493

SEPIA

H

Only for use as an active homoeopathic ingredient.

The following warning statement is required on the medicine label:

- (MOLLUSC) ‘Contains mollusc’ or ’Contains mollusc products’.

 

4494

SEQUOIA SEMPERVIRENS

A, H

 

4495

SEQUOIADENDRON GIGANTEUM

A, H

 

4496

SERENOA REPENS

A, H

 

4497

SERINE

A, E

 

4498

SERUM ANGUILLAE

H

Only for use as an active homoeopathic ingredient. 

 

4499

SESAME OIL

A, E, H

 

4500

SESAMUM INDICUM

A, E, H

 

4501

SETARIA ITALICA

A, H

 

4502

SHARK CALCIUM CHONDROITIN SULFATE

A

 

4503

SHARK CARTILAGE

A, E

The medicine requires the following warning statement on the medicine label:

- (SHARK) 'Children, pregnant or breastfeeding women, and those who have recently had a heart attack, surgery or a major accident should not consume this product without medical advice' (or words to that effect)

 

4504

SHARK CHONDROITIN SULFATE

A, E

When used as an excipient:

- only for use in topical medicines for dermal application;

- not to be included in medicines intended for use in the eye; and

- the concentration in the medicine must be no more than 0.001%.

 

4505

SHARK POTASSIUM CHONDROITIN SULFATE

A

 

4506

SHARK SODIUM CHONDROITIN SULFATE

A, E

When used as an excipient:

- only for use in topical medicines for dermal application;

- not to be included in medicines intended for use in the eye; and

- the concentration in the medicine must be no more than 0.001%.

 

4507

SHARK-LIVER OIL

A, E

Vitamin A and Colecalciferol are mandatory components of Shark-liver oil.

When for internal use, the maximum recommended daily dose must be no more than 25 micrograms of Vitamin D.

When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.

When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.

When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:

- (VITA2) ‘WARNING: If you are pregnant - or considering becoming pregnant - do not take vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA4) ‘WARNING - When taken in excess of 3000 micrograms retinol equivalents - vitamin A can cause birth defects.’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA3) ‘The recommended daily amount of vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.’

 

4508

SHEA BUTTER

E

 

4509

SHEA BUTTER ETHYL ESTERS

E

Shea butter ethyl esters must:

(a) Only be used in topical medicines for dermal application; and

(b) Not be included in medicines intended for use on broken skin.

The total concentration of shea butter ethyl esters in the medicine must not be more than 30%.

 

 

4510

SHEA BUTTER UNSAPONIFIABLES

E

Only for use in topical medicines for dermal application.

 

4511

SHELLAC

E

 

4512

SHEPHERD'S PURSE HERB DRY

A, H

 

4513

SHEPHERD'S PURSE HERB POWDER

A, H

 

4514

SHERRY WINE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4515

SIGESBECKIA ORIENTALIS

A, E, H

 

4516

SILICA

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4517

SILICA DIMETHYL SILYLATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4%.

 

4518

SILICA SILYLATE

E

Only for use in topical medicines for dermal application.

 

4519

SILICIFIED MICROCRYSTALLINE CELLULOSE

E

Only for use when the route of administration is other than inhalation.

 

4520

SILICON DIOXIDE

A, E, H

Only for use when the route of administration is other than inhalation.

 

4521

SILICONE QUATERNIUM-8

E

Only for use in wash-off topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2.5%.

The medicine requires the following warning statement on the medicine label:

- (EYE) 'Avoid contact with eyes' (or words to that effect).

 

4522

SILVER

H

Only for use as an active homoeopathic ingredient.

When for external use, the total concentration of silver in the medicine must not be more than 1%.

When for oral use:

(a) the total concentration of silver in the medicine must not be more than 0.3%; and

(b) the following warning statement is required on the medicine label:

- ‘Overuse may stain skin or mouth.’ (or words to that effect).

 

4523

SILVER BOROSILICATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine should be no more than 0.6%.  

Silver is a mandatory component of Silver borosilicate when the route of administration is topical.

The concentration of silver in the medicine must be no more than 1%.

 

4524

SILVER NITRATE

H

Only for use as an active homoeopathic ingredient. 

 

4525

SILYBUM MARIANUM

A, E, H

 

4526

SIMABA CEDRON

A, H

 

4527

SIMETHICONE

E

 

4528

SIMMONDSIA CHINENSIS

A, E, H

 

4529

SINAPIS ALBA

A, H

Allyl isothiocyanate is a mandatory component of Sinapis alba when the plant part is seed.

The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.

 

4530

SINAPIS ARVENSIS

A, H

 

4531

SINOMENIUM ACUTUM

A, H

 

4532

SIPHONESTEGIA CHINENSIS

A, H

 

4533

SIRAITIA GROSVENORII

A, E, H

 

4534

SISYMBRIUM OFFICINALE

A, H

 

4535

SKATOLE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4536

SKIPJACK-LIVER OIL

A, E

Vitamin A and Colecalciferol are mandatory components of Skipjack-liver oil.

When for internal use, the maximum recommended daily dose must be no more than 25 micrograms of Vitamin D.

When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.

When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.

When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:

- (VITA2) ‘WARNING: If you are pregnant - or considering becoming pregnant - do not take vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA4) ‘WARNING - When taken in excess of 3000 micrograms retinol equivalents - vitamin A can cause birth defects.’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA3) ‘The recommended daily amount of vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.’

 

4537

SLIPPERY ELM BARK DRY

A, H

 

4538

SLIPPERY ELM BARK POWDER

A, E, H

 

4539

SMILAX ARISTOLOCHIIFOLIA

A, H

 

4540

SMILAX CHINA

A, H

 

4541

SMILAX GLABRA

A, H

 

4542

SMILAX OFFICINALIS

A, E, H

 

4543

SMILAX ORNATA

A, E, H

 

4544

SMOKE EXTRACT

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4545

SODIUM ACETATE

E

 

4546

SODIUM ACETYLATED HYALURONATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4547

SODIUM ACID CITRATE

A, E, H

When sodium acid citrate is used as an active ingredient, only for use in oral medicines.

 

4548

SODIUM ACRYLATES COPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.8%.

 

4549

SODIUM ACRYLATES CROSSPOLYMER-2

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.7 % (w/w).

 

4550

SODIUM ACRYLOYDIMETHYLTAURATE/VP CROSSPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2% (w/w).

 

4551

SODIUM ALGINATE

E

 

4552

SODIUM ASCORBATE

A, E, H

 

4553

SODIUM ASCORBYL PHOSPHATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

When used in a sunscreen, the concentration in the medicine must be no more than 0.1%.

 When used in products other than sunscreens, the concentration in the medicine must be no more than 0.5%.

 

4554

SODIUM ASCORBYL/CHOLESTERYL PHOSPHATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4555

SODIUM BENZOATE

E

 

4556

SODIUM BETA-HYDROXY-BETA-METHYLBUTYRATE

A, H

 

4557

SODIUM BETA-HYDROXY-BETA-METHYLBUTYRATE MONOHYDRATE

A, H

 

4558

SODIUM BICARBONATE

A, E

When used as an active ingredient, the medicine may only be for oral rehydration salts in powdered and effervescent tablet dosage forms.

Medicines containing sodium bicarbonate for use as oral rehydration therapy are subject to the following conditions:

a) the medicine complies with the requirements specified in the British Pharmacopoeia, as in force or existing from time to time, for Oral Rehydration Salts;

b) the sodium content and total osmolarity of the solution after it has been prepared according to the instructions on the packet are consistent with the criteria specified by the World Health Organisation (WHO) and the United Nations Childrens Fund (UNICEF) in the document 'Expert consultation on oral rehydration salts formulation 18 July 2001.'

c) the following warning statements are required on the medicine label:

- (UOAD) 'Use only as directed.'

- (DIAR) 'If diarrhoea persists for more than 6 hours in infants under 6 months - 12 hours in children under 3 years - 24 hours in children aged 3-6 years or 48 hours in adults and children over 6 years - seek medical advice (or words to that effect).'

- (DIAR3) 'If diarrhoea persists, seek medical advice.'

 

4559

SODIUM BISULFITE

E

 

4560

SODIUM BROMIDE

H

Only for use as an active homoeopathic ingredient.

The total concentration of sodium bromide in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.

 

4561

SODIUM BUTYRATE

A, E

The route of administration for medicines that contain sodium butyrate must be limited to oral.

The maximum recommended daily dose of the medicine must not provide more than 1200 mg sodium butyrate.

The following warning statement (or words to the same effect) is required on the medicine label:

- (ADULT) 'Adults only’.

 

4562

SODIUM C14-16 OLEFIN SULFONATE

E

Only for use in topical medicines for dermal application.

 

4563

SODIUM CALCIUM EDETATE

E

When for oral use, sodium is a mandatory component of sodium calcium edetate.

Sodium calcium edetate must only be included in medicines when:

(a) the route of administration is limited to topical for dermal use; or

(b) in combination with other permitted ingredients as a flavour proprietary excipient formulation.

The total concentration of sodium calcium edetate in the medicine must not exceed 0.32%.

The total concentration of flavour proprietary excipient formulations containing sodium calcium edetate must not be more than 5% of the total medicine.

 

4564

SODIUM CARBOMER

E

Only for use as an excipient in topical medicines for dermal application.

 

4565

SODIUM CARBONATE

E

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

 

4566

SODIUM CARBONATE MONOHYDRATE

E

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

 

4567

SODIUM CARBOXYMETHYL BETAGLUCAN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.005%.

 

4568

SODIUM CARRAGEENAN

E

 

4569

SODIUM CASEINATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4570

SODIUM CETOSTEARYL SULFATE

E

Only for use in topical medicines for dermal application.

 

4571

SODIUM CHLORIDE

A, E, H

 

4572

SODIUM CHONDROITIN SULFATE

A, E

When used as an excipient ingredient:

a) only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye;

b) the concentration in the medicine must not be more than 0.001%.

When used as an active ingredient:

a) the route of administration must only be oral;

b) the maximum daily dose must not provide more than 1,200 mg of sodium chondroitin sulfate;

c) the following statements must be included on the medicine label:

- (ADULT) ‘Adults only' (or words to that effect);

- (PREGNT) ‘Not recommended for use by pregnant and lactating women’ (or words to that effect).

 

4573

SODIUM CITRATE

A, E

When for use as an active ingredient, only for oral use.

 

4574

SODIUM CITRATE DIHYDRATE

A, E

When for use as an active ingredient, only for oral use.

 

4575

SODIUM COCO PG-DIMONIUM CHLORIDE PHOSPHATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.05%.

 

4576

SODIUM COCOAMPHOACETATE

E

Only for use in topical medicines for dermal application.

 

4577

SODIUM COCOYL SARCOSINATE

E

Only for use in topical medicines for dermal application.

 

4578

SODIUM CYCLAMATE

E

 

4579

SODIUM DEHYDROACETATE

E

Only for use in topical medicines for dermal application.

 

4580

SODIUM DNA

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. 

The concentration in the medicine must be no more than 0.1%.

 

4581

SODIUM DODECYLBENZENESULFONATE

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 30%.

 

4582

SODIUM ERYTHORBATE

E

 

4583

SODIUM ETHYL HYDROXYBENZOATE

E

 

4584

SODIUM FLUORIDE

A, E, H

Fluoride is a mandatory component of sodium fluoride.

The route of administration must be limited to dental.

The dosage form must be limited to pastes, powders and/or gels for dental hygiene.

When used as an active ingredient, the medicine is subject to the following conditions:

(a) only for use in combination with at least one other active ingredient; and

(b) the concentration of fluoride ion in the medicine must not be more than 1,500 mg/kg.

When the concentration of fluoride ion is more than 1000 mg/kg, the medicine requires the following statements on the medicine label:

- (DNTSW) 'Do not swallow.'

- (CHILD4) 'Do not use [this product/insert name of product] in children 6 years of age or less.'

 

4585

SODIUM FUMARATE

E

 

4586

SODIUM HYALURONATE

A, E

When for use as an excipient ingredient, sodium hyaluronate must only be used in medicines with a topical route of administration for dermal application.

When for use as an active ingredient:

(a) the molecular mass of sodium hyaluronate must be between 600 and 1600 kilodaltons; and

(b) sodium hyaluronate must only be used in medicines when the route of administration is limited to:

(i) topical for dermal application; or

(ii) oral.

When for use in a topical medicine for dermal application the concentration of sodium hyaluronate in the medicine must not exceed 2.0%.

When for use as an active ingredient and the route of administration is oral:

(a) the maximum recommended daily dose must not provide more than 200 milligrams sodium hyaluronate;

(b) the recommended duration of use of the medicine must be limited to three months; and

(c) the following warning statements (or words to the same effect) are required on the medicine label :

- (ADULT) 'Adults only’; and

- (PREGNT) ' Not recommended for use by pregnant and lactating women'.

 

4587

SODIUM HYDROGENATED TALLOW GLUTAMATE

E

Only for use in topical medicines for dermal application.

 

4588

SODIUM HYDROXIDE

E

The concentration of sodium hydroxide in the medicine must not be more than 5%.

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

 

4589

SODIUM HYDROXYCITRATE

A

 

4590

SODIUM HYDROXYETHYL ACRYLATE/ACRYLOYLDIMETHYL TAURATE COPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.5%.

 

4591

SODIUM HYDROXYMETHYLGLYCINATE

E

Only for use in topical medicines for dermal application.

 

4592

SODIUM HYPOCHLORITE

E

Chlorine is a mandatory component of sodium hypochlorite.

The concentration of chlorine in the medicine must not be more than 4%.

 

4593

SODIUM ISOSTEAROYL LACTYLATE

E

Only for use in topical medicines for dermal application.

 

4594

SODIUM LACTATE

E

 

4595

SODIUM LAURETH SULFATE

E

 

4596

SODIUM LAUROAMPHOACETATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4597

SODIUM LAUROYL LACTYLATE

E

Sodium lauroyl lactylate must:

(a) Only be used in topical medicines for dermal application; and

(b) Not be included in medicines intended for use on broken skin or in the eye.

The concentration in the medicine must be no more than 0.2%.

 

4598

SODIUM LAUROYL METHYL ISETHIONATE

E

Only for use in wash-off topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 11%.

 

4599

SODIUM LAUROYL SARCOSINATE

E

Only for use in topical medicines for dermal application.

 

4600

SODIUM LAURYL PHOSPHATE

E

 

4601

SODIUM LAURYL SULFATE

E

 

4602

SODIUM LAURYL SULFOACETATE

E

Only for use in topical medicines for dermal application.

 

4603

SODIUM MAGNESIUM SILICATE

E

Only for use in topical medicines for dermal application.

 

4604

SODIUM MANNOSE PHOSPHATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

4605

SODIUM METABISULFITE

E

 

4606

SODIUM METAPHOSPHATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or damaged skin.

The concentration in the medicine must not be more than 0.1%.

 

4607

SODIUM METHYL COCOYL TAURATE

E

Only for dental use.

The concentration in the medicine must be no more than 2%.

 

4608

SODIUM METHYL HYDROXYBENZOATE

E

 

4609

SODIUM MOLYBDATE DIHYDRATE

A

Only for use in oral medicines.

Molybdenum is a mandatory component of Sodium molybdate dihydrate.

The percentage of molybdenum from sodium molybdate dihydrate should be calculated based on the molecular weight of sodium molybdate dihydrate.

The maximum daily dose of molybdenum from Sodium molybdate dihydrate must be no more than 125 micrograms.

 

4610

SODIUM MONOFLUOROPHOSPHATE

A

Fluoride is a mandatory component of sodium monofluorophosphate.

The route of administration must be limited to dental.

The dosage form must be limited to pastes, powders and/or gels for dental hygiene.

When sodium monofluorophosphate is used as an active ingredient, it is subject to the following conditions:

(a) only for use in combination with at least one other active ingredient; and

(b) the concentration of fluoride ion in the medicine must not be more than 1,500 mg/kg.

When the concentration of fluoride ion is more than 1000 mg/kg, the following warning statements are required on the medicine label:

- (DNTSW) 'Do not swallow.'

- (CHILD4) 'Do not use [this product/insert name of product] in children 6 years of age or less.'

 

4611

SODIUM MYRISTOYL GLUTAMATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. 

The concentration in the medicine must be no more than 0.0164%.

 

4612

SODIUM NITRATE

H

Only for use as an active homoeopathic ingredient.

 

4613

SODIUM NONOXYNOL-4 SULFATE

E

Only for use in topical medicines for dermal application.

 

4614

SODIUM PANTOTHENATE

A, E, H

 

4615

SODIUM PCA

E

Only for use in topical medicines for dermal application.

 

4616

SODIUM PERBORATE

A, H

Boron is a mandatory component of sodium perborate.

When for internal use, the maximum recommended daily dose must not provide more than 6 mg of boron.

When used in preparations for dermal use, which are not for paediatric or antifungal use, the concentration of boron from all ingredients in the product must not exceed 3500 mg/kg or 3500 mg/L or 0.35%.

When the maximum recommended daily dose of the medicine provides more than 3 mg of boron and the medicine is for internal use and/or oral application, one of the following warning statements is required on the label:

- (NTAKEN12) 'Not to be taken by children under 12 years old' (or words to that effect); or

- (ADULT) 'Adults only' (or words to that effect).

When the maximum recommended daily dose of the medicine provides more than 1 mg boron and up to, and including, 3 mg of boron, and the medicine is for internal use and/or oral application, one of the following warning statements is required on the label:

- (NTAKEN2) 'Not to be taken by children under 2 years old' (or words to that effect); or

- (ADULT) 'Adults only' (or words to that effect).

When for excipient use and the maximum recommended daily dose of the medicine provides more than 1 mg of boron and the medicine is for internal use and/or oral application, the following warning statement is required on the label:

- (BORON) 'Contains boron' (or words to that effect).

When the medicine is for topical use for dermal application, the following warning statement is required on the label:

- (BROKEN) 'Use on unbroken skin only' (or words to that effect).

 

4617

SODIUM PERCARBONATE

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 15%.

 

4618

SODIUM POLYACRYLATE

E

Only for use in topical medicines for dermal application.

 

4619

SODIUM POLYACRYLATE STARCH

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 1%.

 

4620

SODIUM POLYMETAPHOSPHATE

E

 

4621

SODIUM PROPIONATE

E

 

4622

SODIUM PROPYL HYDROXYBENZOATE

E

 

4623

SODIUM RNA

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.2%.

 

4624

SODIUM SELENATE

A, H

Selenium is a mandatory component of sodium selenate.

Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.'

 

4625

SODIUM SELENATE DECAHYDRATE

A

Selenium is a mandatory component of sodium selenate decahydrate.

Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.'

 

4626

SODIUM SELENITE

A, H

Selenium is a mandatory component of Sodium selenite.

Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.’

 

4627

SODIUM SELENITE PENTAHYDRATE

A

Selenium is a mandatory component of Sodium selenite pentahydrate.

Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.’

 

4628

SODIUM SILICATE

E

 

4629

SODIUM STARCH GLYCOLLATE

E

 

4630

SODIUM STARCH GLYCOLLATE TYPE A

E

 

4631

SODIUM STEARATE

E

Only for use in topical medicines for dermal application.

 

4632

SODIUM STEAROXY PG-HYDROXYETHYLCELLULOSE SULFONATE

E

Only for use in topical medicines for dermal application and not to be used in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

4633

SODIUM STEAROYL GLUTAMATE

E

Only for use in topical medicines for dermal application and not to be used in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 2.5%.

 

4634

SODIUM STEAROYL LACTYLATE

E

Only for use in topical medicines for dermal application.

 

4635

SODIUM STEARYL PHTHALAMATE

E

Only for use in medicines for dermal application and not to be used in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.5%.

 

4636

SODIUM SUCCINATE

E

Only for use in topical medicines for dermal application.

 

4637

SODIUM SULFATE

A, E, H

When it is not intended to be a laxative, the following warning statement is required on the medicine label:

- (LAX4) 'Substance may have a laxative effect'.

 

4638

SODIUM SULFATE DECAHYDRATE

A, E, H

When it is not intended to be a laxative, the following warning statement is required on the medicine label:

- (LAX4) 'Substance may have a laxative effect'.

 

4639

SODIUM SULFITE

E

 

4640

SODIUM SULFITE HEPTAHYDRATE

E

Only for use in topical medicines for dermal application.

 

4641

SODIUM TRIPOLYPHOSPHATE

E

Only for use when the route of administration is topical for dermal application, mucous membrane (buccal mucosa) or dental.

Not to be included in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4642

SOLANUM DULCAMARA

A, H

When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum dulcamara.

When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.

 

4643

SOLANUM FEROX

A, H

When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum ferox.

When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.

 

4644

SOLANUM LYCOCARPUM FRUIT EXTRACT

E

Only for use in topical medicines for dermal use and not to be included in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.02%.

 

4645

SOLANUM MELONGENA

A, H

When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum melongena.

When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.

 

4646

SOLANUM NIGRUM

A, H

When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum nigrum.

When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.

 

4647

SOLANUM TUBEROSUM

A, H

When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum tuberosum.

When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.

 

4648

SOLIDAGO GIGANTEA

A, H

 

4649

SOLIDAGO GIGANTEA MIS

A, E, H

 

4650

SOLIDAGO VIRGAUREA

A, E, H

 

4651

SOLUBLE MAIZE STARCH

E

 

4652

SOLUBLE POTATO STARCH

E

 

4653

SOLVENT GREEN 3

E

Permitted for use only as a colour for topical use.

 

4654

SOLVENT RED 1

E

Permitted for use only as a colour for topical use.

 

4655

SOLVENT VIOLET 13

E

Permitted for use only as a colour for topical use.

 

4656

SOLVENT YELLOW 172

E

Permitted for use only as a colour for topical use.

The concentration in the medicine must be no more than 0.3%.

 

4657

SOLVENT YELLOW 33

E

Permitted for use only as a colour for topical use.

 

4658

SOPHORA FLAVESCENS

A, E, H

 

4659

SOPHORA TONKINENSIS

A, H

 

4660

SORBIC ACID

E

 

4661

SORBITAN ISOSTEARATE

E

Only for use in topical medicines for dermal application.

 

4662

SORBITAN MONO-OLEATE

E

 

4663

SORBITAN MONOLAURATE

E

 

4664

SORBITAN MONOSTEARATE

E

 

4665

SORBITAN OLEATE

E

 

4666

SORBITAN OLIVATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 10%.

 

4667

SORBITAN PALMITATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2%.

 

4668

SORBITAN SESQUIISOSTEARATE

E

Only for use in topical medicines for dermal application.

 

4669

SORBITAN SESQUIOLEATE

E

Only for use in topical medicines for dermal application.

 

4670

SORBITAN STEARATE

E

 

4671

SORBITAN TRISTEARATE

E

Only for use in topical medicines for dermal application.

 

4672

SORBITOL

A, E

When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.

 

4673

SORBITOL SOLUTION (70 PER CENT) (CRYSTALLISING)

A, E

Sorbitol is a mandatory component of sorbitol solution (70 per cent) (crystallising).

When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.

 

4674

SORBITOL SOLUTION (70 PER CENT) (NON-CRYSTALLISING)

A, E

Sorbitol is a mandatory component of sorbitol solution (70 per cent) (non-crystallising).

When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.

 

4675

SORBUS AUCUPARIA

A, H

 

4676

SORGHUM

E

 

4677

SORGHUM VULGARE

A, H

 

4678

SOY PHOSPHATIDYLSERINE-ENRICHED SOY LECITHIN LIQUID

A

Soy phosphatidylserine is a mandatory component of soy phosphatidylserine-enriched soy lecithin liquid.

The requirement specified in paragraph (a) below applies to a medicine that contains the ingredient that is:

- listed in the Register before 1 March 2024; and

- released for supply before 1 March 2025.

(a) The concentration of soy phosphatidylserine in the medicine must be no more than 15%.

The requirement specified in paragraph (b) below applies to a medicine that contains the ingredient that is:

- listed in the Register on or after 1 March 2024; or

- released for supply on or after 1 March 2025.

(b) The maximum recommended daily dose of the medicine must not provide more than 300 mg of soy phosphatidylserine.

 

4679

SOY PHOSPHATIDYLSERINE-ENRICHED SOY LECITHIN POWDER

A

Soy phosphatidylserine is a mandatory component of soy phosphatidylserine-enriched soy lecithin powder.

The requirement specified in paragraph (a) below applies to a medicine that contains the ingredient that is:

- listed in the Register before 1 March 2024; and

- released for supply before 1 March 2025.

(a) The concentration of soy phosphatidylserine in the medicine must be no more than 15%.

The requirement specified in paragraph (b) below applies to a medicine that contains the ingredient that is:

- listed in the Register on or after 1 March 2024; or

- released for supply on or after 1 March 2025.

(b) The maximum recommended daily dose of the medicine must not provide more than 300 mg of soy phosphatidylserine.

 

4680

SOY POLYSACCHARIDE

E

 

4681

SOY PROTEIN

E

 

4682

SOY STEROL

E

 

4683

SOYA BEAN

E

 

4684

SOYA OIL

A, E, H

 

4685

SOYBEAN FLOUR

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4686

SOYBEAN GLYCERIDES

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4%.

 

4687

SPARGANIUM STOLONIFERUM

A, H

 

4688

SPARTIUM JUNCEUM

A, H

 

4689

SPATHOLOBUS SUBERECTUS

A, H

 

4690

SPEARMINT OIL

A, E, H

Menthol is a mandatory component of spearmint oil.

When the medicine is for topical use for dermal application:

(i) the medicine must not be intended for use in the eye or on damaged skin;

(ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;

(iii) the following warning statement is required on the medicine label:

- (EYE) Avoid contact with eyes (or words to that effect).

(iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use.

(v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label:

– (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.

When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

4691

SPEARMINT OIL TERPENELESS

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Menthol is a mandatory component of spearmint oil terpeneless.

When the medicine is for topical use for dermal application:

i) the medicine must not be intended for use in the eye or on damaged skin;

ii) the medicine must not deliver more than 25% total menthol when administered according to the directions for use;

iii) the following warning statement is required on the medicine label:

- (EYE) Avoid contact with eyes (or words to that effect).

iv) if the medicine delivers more than 1% total menthol when administered according to the directions for use, the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use.

v) if the medicine delivers more than 5% total menthol when administered according to the directions for use, the following warning statement is required on the medicine label:

– (MENTH) Contains a high concentration of menthol, which can cause severe skin irritation.

When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

4692

SPHINGOLIPIDS

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

4693

SPIGELIA ANTHELMIA

A, H

 

4694

SPIGELIA MARILANDICA

A, H

The maximum recommended daily dose must be no more than the equivalent of 1mg of the dry herbal material.

 

4695

SPIKE LAVENDER OIL

A, E, H

Camphor is a mandatory component of spike lavender oil.

In solid and semi solid preparations, the concentration of camphor must be no more than 12.5%.

In liquid preparations other than essential oils, the concentration of camphor must be no more than 2.5%.

In essential oil preparations, if the concentration of camphor is more than 2.5% but less than or equal to 10%, and the nominal capacity of the container is less than 25 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is less than 15 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, the medicine must have a restricted flow insert and child resistant closure fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

If the concentration of camphor is more than 2.5%, the nominal capacity of the container must be no more than 25 millilitres.

 

4696

SPINACH

E

 

4697

SPINACIA OLERACEA

A, E, H

 

4698

SPIRODELA POLYRRHIZA

A, H

 

4699

SPIRULINA

E

 

4700

SPRAY-DRIED GLUCOSE SYRUP

E

Permitted for use as an excipient for oral routes of administration.

 

4701

SPRAY-DRIED LIQUID GLUCOSE

E

Permitted for use as an excipient for oral routes of administration.

 

4702

SPRUCE OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4703

SQUALANE

E

Only for use in topical medicines for dermal application.

 

4704

SQUALENE

A, E

 

4705

SQUID OIL

A

Only for use in oral medicines.

Must be obtained from species of the order Teuthida of the class Cephalopoda, be used in combination with other ingredients in the medicine and be presented in a therapeutic dosage form for therapeutic use.

The following warning statement is required on the medicine label:

- (MOLLUSC) ‘Contains mollusc’ or ’Contains mollusc products’.

 

4706

SQUILL DRY

A, H

 

4707

SQUILL INDIAN DRY

A, H

 

4708

SQUILL INDIAN POWDER

A, H

 

4709

SQUILL POWDER

A, H

 

4710

ST JOHN'S WORT DRY EXTRACT QUANTIFIED

A

When used for oral ingestion, the medicine requires the following warning statement on the medicine label:

- (STJOHN) 'St John's Wort affects the way many prescription medicines work - including oral contraceptives. Consult your doctor.'

 

4711

ST JOHN'S WORT HERB DRY

A, H

When used for oral ingestion, the medicine requires the following warning statement on the medicine label:

- (STJOHN) 'St John's Wort affects the way many prescription medicines work - including oral contraceptives. Consult your doctor.'

 

4712

ST JOHN'S WORT HERB POWDER

A, H

When used for oral ingestion, the medicine requires the following warning statement on the medicine label:

- (STJOHN) 'St John's Wort affects the way many prescription medicines work - including oral contraceptives. Consult your doctor.'

 

4713

STACHYS OFFICINALIS

A, E, H

 

4714

STACHYS PALUSTRIS

A, H

 

4715

STACHYURUS HIMALAICUS

A, H

 

4716

STANNIC OXIDE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.005%.

 

4717

STANNOUS CHLORIDE

H

Only for use as an active homoeopathic ingredient. 

 

4718

STAR ANISE OIL

A, E

When the total concentration of star anise oil in the medicine is more than 50%:

(a) the nominal capacity of the container must not be more than 50 mL;

(b) a restricted flow insert must be fitted on the container; and

(c) the following warning statement is required on the medicine label:

- (CHILD) ‘Keep out of reach of children’ (or words to that effect).

 

4719

STARCH

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4720

STARCH SODIUM OCTENYL SUCCINATE

E

 

4721

STEARALKONIUM CHLORIDE

E

Only for use in topical medicines for dermal application.

 

4722

STEARALKONIUM HECTORITE

E

Only for use in topical medicines for dermal application.

 

4723

STEARAMIDE

E

Only for use in topical medicines for dermal application.

 

4724

STEARAMIDOETHYL DIETHYLAMINE

E

Only for use in topical medicines for dermal application.

 

4725

STEARAMIDOPROPYL DIMETHYLAMINE

E

Only for use in topical medicines for dermal application.

 

4726

STEARAMIDOPROPYL PG-DIMONIUM CHLORIDE PHOSPHATE

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 2%.

When the medicine is intended to be used on the eye, the medicine requires the following warning statement on the medicine label:

- (EYE2) 'May be irritant to the eyes' (or words to that effect).

 

4727

STEARETH-10

E

Only for use in topical medicines for dermal application.

 

4728

STEARETH-100

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.5%.

 

4729

STEARETH-2

E

Only for use in topical medicines for dermal application.

 

4730

STEARETH-20

E

Only for use in topical medicines for dermal application.

 

4731

STEARETH-21

E

Only for use in topical medicines for dermal application.

 

4732

STEARETH-5

E

Only for use in topical medicines for dermal application.

 

4733

STEARIC ACID

E

 

4734

STEAROPTENES

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4735

STEAROXY DIMETHICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4%.

 

4736

STEAROXYTRIMETHYLSILANE

E

Only for use in topical medicines for dermal application.

 

4737

STEAROYL MACROGOLGLYCERIDES

E

Only for use in oral medicines.

The concentration in the medicine must be no more than 0.6%.

 

4738

STEARYL ACETATE

E

Only for use in topical medicines for dermal application.

 

4739

STEARYL ALCOHOL

E

 

4740

STEARYL BEHENATE

E

Only for use as an excipient ingredient for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 3.5% in the final formulation.

 

4741

STEARYL DIMETHICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4.5%.

The medicine requires the following warning statements on the medicine label:

- (EYE2) 'May be irritant to the eyes' (or words to that effect)

- (EYE) 'Avoid contact with eyes' (or words to that effect).

 

4742

STEARYL GLYCYRRHETINATE

E

Only for use in topical medicines for dermal application.

 

4743

STEARYL HEPTANOATE

E

Only for use in topical medicines for dermal application.

 

4744

STEARYL MYRISTATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4745

STEARYL STEARATE

E

Only for use in topical medicines for dermal application.

 

4746

STELLARIA CHAMAEJASME

A, H

 

4747

STELLARIA DICHOTOMA

A, H

 

4748

STELLARIA MEDIA

A, E, H

 

4749

STEMONA JAPONICA

A, H

 

4750

STEMONA SESSILIFOLIA

A, H

 

4751

STENOTAPHRUM SECUNDATUM

A, H

 

4752

STEPHANIA TETRANDA

A, H

 

4753

STERCULIA

A, H

 

4754

STERCULIA TRAGACANTHA

A, H

 

4755

STERCULIA URENS

A, H

 

4756

STEVIA REBAUDIANA

A, E, H

 

4757

STEVIOL GLYCOSIDES

E

Only for use in oral medicines.

 

4758

STILLINGIA SYLVATICA

A, H

 

4759

STORAX PREPARED

A, E, H

 

4760

STRAWBERRY

E

 

4761

STRAWBERRY ESSENCE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4762

STREPTOCOCCUS SALIVARIUS

A

Only permitted for use in medicines:

- that are for oral routes of administration; and

- when the strain of Streptococcus salivarius is confirmed to be K12 or M18.

The name of the Streptococcus salivarius strain must be declared on the label.

The following warning statement is required on the medicine label:

- (CHILD5) 'Use in children under 3 years is not recommended'.

 

4763

STREPTOCOCCUS THERMOPHILUS

A

 

4764

STROBILANTHES CUSIA

A, H

 

4765

STRONG AMMONIA SOLUTION

E

Ammonia is a mandatory component of strong ammonia solution.

The concentration of ammonia in the medicine must be no more than 0.5%.

When for internal use, the concentration in the medicine must be no more than 0.25%.

 

4766

STRONTIUM CARBONATE

H

Only for use as an active homoeopathic ingredient. 

 

4767

STROPHANTHUS GRATUS

H

Only for use as an active homoeopathic ingredient.

 

4768

STROPHANTHUS HISPIDUS

H

Only for use as an active homoeopathic ingredient.

 

4769

STRYCHNOS IGNATII

H

Only for use as an active homoeopathic ingredient.

Strychnine (of Strychnos spp.) is a mandatory component of Strychnos ignatii.

The concentration of Strychnine (of Strychnos spp.) must not be more than 1 milligram/Kg or 1 milligram/L or 0.0001%.

 

4770

STRYCHNOS NUX-VOMICA

A, H

Strychnine (of Strychnos spp.) is a mandatory component of Strychnos nux-vomica.

The concentration of Strychnine (of Strychnos spp.) must not be more than 1 milligram/Kg or 1 milligram/L or 0.0001%.

 

4771

STYPHNOLOBIUM JAPONICUM

A, E, H

 

4772

STYRALLYL PROPIONATE

E

Only for use in medicines in combination with other permitted ingredients as a fragrance proprietary excipient formulation.

The total fragrance proprietary excipient formulation in a medicine must not be more than 1%.

 

4773

STYRAX BENZOIN

A, E, H

 

4774

STYRAX OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4775

STYRAX PARALLELONEURUM

A, H

 

4776

STYRAX TONKINENSIS

A, H

 

4777

STYRENE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

The total concentration of styrene in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.

 

4778

STYRENE/ACRYLATES COPOLYMER

E

Only for use in topical medicines for dermal application.

 

4779

STYROLYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4780

SUBLIMED SULFUR

H

Only for use as an active homoeopathic ingredient. 

 

4781

SUCCINIC ACID

E

 

4782

SUCRALOSE

E

 

4783

SUCROSE

E

 

4784

SUCROSE ACETATE ISOBUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4785

SUCROSE ACETATE PALMITATE STEARATE

E

Only for use in topical medicines for dermal application and not intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.3%.

 

4786

SUCROSE COCOATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

4787

SUCROSE DISTEARATE

E

Only for use in topical medicines for dermal application.

 

4788

SUCROSE LAURATE

E

When for oral or sublingual use, sucrose is a mandatory component of sucrose laurate.

 

4789

SUCROSE OCTAACETATE

E

When for oral or sublingual use, sucrose is a mandatory component of sucrose octaacetate.

 

4790

SUCROSE PALMITATE

E

Only for use in topical medicines for dermal application.

 

4791

SUCROSE POLYCOTTONSEEDATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

 The concentration in the medicine must be no more than 1%.

The medicine requires the following warning statements on the medicine label:

- (EYE) 'Avoid contact with the eyes' (or words to that effect)

- (EYE2) 'May be irritant to the eyes' (or words to that effect).

 

4792

SUCROSE STEARATE

E

For use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

When for topical use, the concentration in the medicine must be no more than 0.25%.

For oral use as a manufacturing aid only.

When for oral use, the concentration in the medicine must be no more than 0.2 mg per dosage unit.

 

4793

SUCROSE TRISTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2%.

 

4794

SUDAN III

E

Permitted for use only as a colour for topical use.

 

4795

SUGAR CANE WAX ALCOHOLS

A, H

The routes of administration for medicines that contain sugar cane wax alcohols must be limited to:

(a) topical for dermal use; and

(b) oral.

When for use in topical medicines, the maximum recommended daily dose of the medicine must not provide more than 12 mg of sugar cane wax alcohols.

When for oral use:

(a) the maximum recommended daily dose of the medicine must not provide more than:

(i) 12 mg of sugar cane wax alcohols for individuals aged less than 18 years; and

(ii) 20 mg of sugar cane wax alcohols for individuals aged 18 years and above.

(b) The following warning statement (or words to the same effect) is required on the medicine label:

- (PREGNT) 'Not recommended for use by pregnant and lactating women'.

(c) If the maximum recommended daily dose of the medicine contains 20 mg of sugar cane wax alcohols, the following warning statement is also required on the medicine label:

- (ADULTS) ‘Adults only’.

 

4796

SUGARCANE

E, H

When for oral or sublingual use, sucrose is a mandatory component of sugarcane.

 

4797

SULFATED CASTOR OIL

E

Only for use in topical medicines for dermal application.

 

4798

SULFATED LOW MOLECULAR WEIGHT FUCANS

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.025%.

 

4799

SULFUR DIOXIDE

E

 

4800

SULFUR IODIDE

H

Only for use as an active homoeopathic ingredient. 

 

4801

SULFURIC ACID

E, H

Only for use as an active homoeopathic ingredient or excipient ingredient. 

The concentration in the medicine must be no more than 0.5%.

 

4802

SULFURISED 1-METHYL-4-(1-METHYLETHENYL)-CYCLOHEXENE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4803

SULISOBENZONE

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 10%.

When used in primary sunscreen products, the following warning statements are required on the label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

4804

SULISOBENZONE SODIUM

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 10%.

When used in primary sunscreen products, the following warning statements are required on the label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

4805

SUNFLOWER OIL

A, E, H

 

4806

SUNFLOWER SEED

E, H

 

4807

SUNSET YELLOW FCF

E

Permitted for use only as a colour for either topical use or with an oral route of administration.

 

4808

SUNSET YELLOW FCF ALUMINIUM LAKE

E

Permitted for use only as a colour in medicines limited to topical and oral routes of administration.

 

4809

SUPEROXIDE DISMUTASE

E

Only for use in topical medicines for dermal application.

 

4810

SWEDE

E

 

4811

SWEET ORANGE OIL TERPENES AND TERPENOIDS

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4812

SWEET POTATO

E

 

4813

SWERTIA CHIRATA

A, H

 

4814

SWIETENIA MAHOGANI

A, H

 

4815

SYAGRUS ROMANZOFFIANA

A, E, H

 

4816

SYMPHYOTRICHUM NOVI-BELGII

A, H

 

4817

SYMPHYTUM OFFICINALE

H

When used orally as an active homoeopathic ingredient, the concentration must be a dilution of 12X or more.

When used in topical medicines for dermal application, the concentration in the preparation must be no more than 10mg/kg or 10mg/L or 0.001%.

 

4818

SYMPLOCARPUS FOETIDUS

A, H

 

4819

SYNTHETIC BEESWAX

E

Only for use in topical medicines for dermal applications.

 

4820

SYNTHETIC TERPENE RESIN

E

Only for use in topical, oral or oral application medicines.

When the route of administration is oral, the dosage form must be chewing gum.

 

4821

SYNTHETIC WAX

E

 

4822

SYRINGA RETICULATA

A, H

 

4823

SYRINGA VULGARIS

A, H

 

4824

SYZYGIUM AROMATICUM

A, E, H

When the plant preparation is oil or distillate and the concentration of this oil or distillate in the product is greater than 25%, the nominal capacity of the container must be no more than 25 millilitres and the medicine must include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

When the plant preparation is oil or distillate, the concentration of this oil or distillate in the medicine is greater than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, a child resistant closure and restricted flow insert must be fitted on the container.

When the plant preparation is oil or distillate, the concentration of oil or distillate in the product is greater than 25% and the nominal capacity of the container is less than 15 millilitres, a restricted flow insert must be fitted on the container.

When the plant preparation is oil or distillate and the preparation is for topical use in the mouth, the preparation may not contain more than 5 millilitres of the oil or distillate and the concentration of oil or distillate in the product must not be greater than 25%.

 

4825

SYZYGIUM CUMINI

A, H

 

4826

SYZYGIUM JAMBOS

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 0.0693%.

 

4827

TABEBUIA SERRATIFOLIA

A, E, H

 

4828

TADEHAGI TRIQUETRUM

A, H

 

4829

TAGETES ERECTA

A, E, H

When used as an excipient ingredient, only for use in combination with other permitted ingredients as a flavour proprietary excipient formulation. The total flavour proprietary excipient formulation in a medicine must not be more than 5%.

 

4830

TAGETES MINUTA

A, E, H

 

4831

TAGETES OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4832

TAIPAN SNAKE

H

Only for use as an active homoeopathic ingredient.

 

4833

TALLOW

E

Only for use in topical medicines for dermal application.

 

4834

TALLOW GLYCERIDES

E

 

4835

TAMARINDUS INDICA

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4836

TAMARIX APHYLLA

A, H

 

4837

TAMARIX CHINENSIS

A, H

 

4838

TAMARIX GALLICA

A, H

 

4839

TAMUS COMMUNIS

A, H

If the plant part is fruit or root, the maximum recommended daily dose must be no more than 1mg of the equivalent dry fruit or dry root of Tamus communis.

 

4840

TANACETUM CINERARIIFOLIUM

A, H

The concentration in the medicine must be no more than 10%.

 

4841

TANACETUM COCCINEUM SUBSP. COCCINEUM

A, H

 

4842

TANACETUM PARTHENIUM

A, E, H

 

4843

TANACETUM VULGARE

A, H

Oil (of Tanacetum vulgare) is a mandatory component of Tanacetum vulgare.

The concentration of oil (of Tanacetum vulgare) in the medicine must be no more than 0.8%.

 

4844

TANGERINE OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4845

TANGERINE OIL COLDPRESSED

A, E, H

When used internally, oxedrine is a mandatory component of tangerine oil coldpressed.

The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams.

 

4846

TANNIC ACID

E

 

4847

TAPIOCA STARCH

E

 

4848

TARAXACUM MONGOLICUM

A, E, H

 

4849

TARAXACUM OFFICINALE

A, E, H

 

4850

TARO

E

 

4851

TARRAGON OIL

A, E, H

 

4852

TARTARIC ACID

E

 

4853

TARTRAZINE

E

Only for use as a colour.

Only for use in medicines for topical and oral administration.

 

4854

TARTRAZINE ALUMINIUM LAKE

E

Only for use as a colour.

Only for use in medicines for topical and oral administration.

 

4855

TASMANNIA LANCEOLATA

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4856

TAURINE

A, E

 

4857

TEA-STEARATE

E

Only for use in topical medicines for dermal application.

 

4858

TERMINALIA ARJUNA

A

Only for use in oral medicines.

Only for use when the plant part is bark.

The maximum recommended daily dose must be no more than 6 grams of Terminalia arjuna dried bark or its extract equivalents.

The medicine requires the following warning statements on the medicine label:

- (PREGNT) 'Not recommended for use by pregnant and lactating women' (or words to that effect)

- (CHILD2) 'Not suitable for children'.

 

4859

TERMINALIA BELLIRICA

A

Only for use when the preparation is as an aqueous extract of the fruit pericarp.

 

4860

TERMINALIA CATAPPA

A, H

 

4861

TERMINALIA CHEBULA

A, H

 

4862

TERMINALIA FERDINANDIANA

A, E, H

The requirements specified in paragraphs (a) to (c) below apply to a medicine that contains the ingredient that is:

- listed in the Register before 1 March 2024; and

- released for supply before 1 March 2025.

(a) Only for use when the plant part is fruit flesh, fruit flesh dry or the preparation is as an aqueous extract of the fruit flesh.

(b) When used as an excipient, the ingredient is only for use in topical medicines for dermal application and not to be included in medicines intended for use on damaged skin or in the eye.

(c) When used as an excipient, the concentration in the medicine must be no more than 0.3%.

The requirements specified in paragraphs (d) to (e) below apply to a medicine that contains the ingredient that is:

- listed in the Register on or after 1 March 2024; or

- released for supply on or after 1 March 2025.

(d) When used as an active ingredient:

(i) the plant part must be from fruit flesh or seed only; and

(ii) the plant preparation must be limited to fresh, dry, powder, and extraction preparations with water as the only solvent.

(e) When used as an excipient ingredient:

(i) the route of administration for medicines that contain Terminalia ferdinandiana must be limited to topical for dermal use;

(ii) medicines that contain Terminalia ferdinandiana are not to be intended for use on damaged skin or in the eye; and

(iii) the concentration of Terminalia ferdinandiana in the medicine must not be more than 0.3%.

 

4863

TERMINALIA SERICEA

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

Only for use when the plant part is root bark.

Only methanol/water (90:10; V/V) extract of Terminalia sericea bark of the root is approved.

The concentration in the medicine must be no more than 0.1%.

 

4864

TERPENE RESIN

E

Terpene resin must only be included in medicines when in combination with other permitted ingredients as a proprietary excipient formulation in medicines with a dermal route of administration for topical application.

 

4865

TERPINEN-4-OL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4866

TERPINEOL

E

 

4867

TERPINEOL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4868

TERPINOLENE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4869

TERPINYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4870

TERPINYL BUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used as a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4871

TERPINYL METHYL ETHER

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4872

TERT-BUTYL ALCOHOL

E

Only for use in topical medicines for dermal application.

 

4873

TERT-BUTYL HYDROQUINONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4874

TERT-BUTYL METHYL ETHER

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4875

TERT-BUTYLPYRAZINE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4876

TETRACLINIS ARTICULATA

A, E, H

 

4877

TETRADECYL AMINOBUTYROYLVALYLAMINOBUTYRIC UREA TRIFLUOROACETATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.002%.

 

4878

TETRADIUM RUTICARPUM

A, H

When for internal use, oxedrine is a mandatory component of Tetradium ruticarpum.

The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 mg.

 

4879

TETRAHEXYLDECYL ASCORBATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4880

TETRAHYDRO LINALYLACETATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4881

TETRAHYDRO PARA-METHYLQUINOLINE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4882

TETRAHYDRO-6-(3-PENTENYL)-2H-PYRAN-2-ONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4883

TETRAHYDRODIFERULOYLMETHANE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

4884

TETRAHYDROFURFURYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4885

TETRAHYDROGERANYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4886

TETRAHYDROLINALOOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4887

TETRAHYDROMUGUOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4888

TETRAHYDROMYRCENOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4889

TETRAHYDROXYPROPYL ETHYLENEDIAMINE

E

Only for use in topical medicines for dermal application.

 

4890

TETRAMETHYL ACETYLOCTAHYDRONAPHTHALENES

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4891

TETRAPANAX PAPYRIFER

A, H

 

4892

TETRASODIUM ETIDRONATE

E

Only for use in topical medicines for dermal application.

 

4893

TETRASODIUM PYROPHOSPHATE

E

 

4894

TEUCRIUM CHAMAEDRYS

A, H

The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Teucrium chamaedrys.

 

4895

TEUCRIUM MARUM

A, H

The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Teucrium marum.

 

4896

TEUCRIUM SCORODONIA

A, H

The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Teucrium scorodonia.

 

4897

THAPSIA GARGANICA

A, H

 

4898

THAUMATIN

E

 

4899

THEANINE

A

Only to be used in a medicine where Trans Chem Pty Ltd (Client ID 21878), who applied to have the ingredient included in this Determination, is the sponsor of the medicine or has given written authorisation to the sponsor of a medicine to include the ingredient in the medicine. This paragraph ceases to be a requirement for this ingredient after 1 March 2026.

The route of administration for medicines that contain theanine must be limited to oral.

The maximum recommended daily dose of the medicine must not provide more than 450 mg of theanine.

The following warning statements (or words to the same effect) are required on the medicine label:

- (PREGNT) 'Not recommended for use by pregnant and lactating women'; and

- (ADULT) 'Adults only'.

 

 

4900

THEASPIRANE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4901

THEMEDA TRIANDRA

A, H

 

4902

THEOBROMA CACAO

A, E, H

Caffeine is a mandatory component of Theobroma cacao.

When the medicine is packaged for supply as a divided preparation and is for internal use or oral application, the medicine must not contain a concentration of total caffeine greater than 33%.

When for internal use or oral application, the maximum recommended daily dose of the medicine must provide no more than 400 mg of total caffeine.

When the medicine is packaged for supply as an undivided preparation and is for internal use or oral application, the medicine must not contain a concentration of total caffeine greater than 1%.

When the medicine is for internal use or oral application, a maximum recommended dose of the medicine must not provide more than 100 mg of total caffeine within a 3 hour period.

When the maximum recommended daily dose of the medicine provides greater than 10 mg of total caffeine and the medicine is for internal use or oral application, the following warning statements are required on the label:

- (ADULT) 'Adults only' (or words to that effect).

- (CAFF) 'Contains [state quantity per dosage unit or per mL or per gram of product] total caffeine [per dosage unit or per mL or per gram]. A cup of instant coffee contains approximately 80 mg of caffeine.'

- (CAFFPREG) ‘Caffeine intake more than 200 mg per day is not recommended during pregnancy or breastfeeding.’

When the maximum recommended daily dose of the medicine provides greater than 80 mg of total caffeine and the medicines is for internal use or oral application, the following warning statements are required on the label:

- (CAFFLMT) 'Limit the use of caffeine-containing products (including tea and coffee) when taking this product.'

- (CAFFCYP) ‘Caffeine interacts with enzyme CYP1A2 in the liver. Consult your health professional before taking with other medicines’ (or words to that effect).

 

4903

THEOBROMA OIL

A, E, H

 

4904

THIAMINE

A, E

 

4905

THIAMINE HYDROCHLORIDE

A, E

 

4906

THIAMINE NITRATE

A, E

 

4907

THIOCINEOLE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4908

THIOTAURINE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.02%.

 

4909

THLASPI ARVENSE

A, E, H

 

4910

THREONINE

A, E

 

4911

THUJA OCCIDENTALIS

A, H

 

4912

THUJA PLICATA

A, E, H

 

4913

THYME HERB DRY

A, E, H

 

4914

THYME OIL

A, E, H

When the concentration of Thyme oil in the medicine is more than 50%, the nominal capacity of the container must be no more than 25 mL, a restricted flow insert must be fitted on the container and the medicine requires the warning statement:

- (CHILD) 'Keep out of reach of children' (or words to that effect).

 

4915

THYMOL

A, E

When used as an active ingredient, the medicine must be medicated space spray or medicated throat lozenges.

When used as an excipient, only for use in medicated throat lozenges or topical medicines for dermal applications.

 

4916

THYMOL METHYL ETHER

E

Thymol methyl ether must only be included in medicines when in combination with other permitted ingredients as a flavour proprietary excipient formulation.

The total concentration of the flavour proprietary excipient formulation containing thymol methyl ether must not be more than 5% of the total medicine.

 

4917

THYMUS CAPITATUS

A, E, H

When the plant preparation is an oil, and the concentration in the medicine is more than 50%, the nominal capacity of the container must be no more than 25 mL, a restricted flow insert must be fitted on the container and the medicine requires the following warning statement on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect).

 

4918

THYMUS GLAND

H

Only for use as an active homoeopathic ingredient. 

 

4919

THYMUS MASTICHINA

A, E, H

When the plant preparation is an oil, and the concentration in the medicine is more than 50%, the nominal capacity of the container must be no more than 25 mL, a restricted flow insert must be fitted on the container and the medicine requires the following warning statement on the medicine label:- (CHILD) 'Keep out of reach of children' (or words to that effect).

 

4920

THYMUS SERPYLLUM

A, E, H

When the plant preparation is an oil, and the concentration in the medicine is more than 50%, the nominal capacity of the container must be no more than 25 mL, a restricted flow insert must be fitted on the container and the medicine requires the following warning statement on the medicine label:- (CHILD) 'Keep out of reach of children' (or words to that effect).

 

4921

THYMUS VULGARIS

A, E, H

When the plant preparation is oil or distillate, and the concentration of Thymus vulgaris oil or distillate in the preparation is greater than 50%:

(a) the nominal capacity of the container must not be more than 25 millilitres;

(b) a restricted flow insert must be fitted on the container; and

(c) the following warning statement is required on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect).

 

4922

THYMUS VULGARIS MIS

A, E, H

When the plant preparation is an oil or distillate, and the concentration of Thymus vulgaris MIS oil or distillate in the preparation is greater than 50%:

(a) the nominal capacity of the container must not be more than 25 millilitres;

(b) a restricted flow insert must be fitted on the container; and

(c) the following warning statement is required on the label:

- (CHILD) 'Keep out of reach of children' (or words to that effect).

 

4923

THYMUS ZYGIS

A, H

When the plant preparation is an oil or a distillate, and the concentration of Thymus zygis oil or distillate in the preparation is greater than 50%:

(a) the nominal capacity of the container must not be more than 25 millilitres;

(b) a restricted flow insert must be fitted on the container; and

(c) the following warning statement is required on the label:

- (CHILD) 'Keep out of reach of children' (or words to that effect).

 

4924

TIGER SNAKE

H

Only for use as an active homoeopathic ingredient.

 

4925

TILACTASE

A

Must be derived from Aspergillus oryzae and comply with the relevant USP monograph.

 

4926

TILIA CORDATA

A, E, H

 

4927

TILIA PLATYPHYLLOS

A, E, H

 

4928

TILIA TOMENTOSA

A, H

 

4929

TILIA X VULGARIS

A, E, H

 

4930

TILIANTOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4931

TIN

H

Only for use as an active homoeopathic ingredient. 

 

4932

TINOSPORA CORDIFOLIA

A, H

 

4933

TINOSPORA SINENSIS

A, H

 

4934

TITANIUM DIOXIDE

A, E

For use as an active ingredient only in sunscreens for dermal application.

The concentration in sunscreens must be no more than 25%.

For use as an excipient only as a colour and only in medicines limited to oral and topical routes of administration.

Not to be included in medicines intended for use in the eye.

When used in primary sunscreen products, the following warning statements are required on the label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

4935

TOCOCYSTEAMIDE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.01%.

 

4936

TOCOFERSOLAN

E

Only for oral and topical use.

When for oral use, the concentration in the medicine must be no more than 10% w/w.

When used in topical medicines for dermal application, it is not to be included in medicines intended for use in the eye.

When for topical use, the concentration in the medicine must be no more than 0.1%

 

4937

TOCOPHEROL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4938

TOCOPHERYL GLUCOSIDE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use on damaged skin or in the eye.

The concentration in the medicine must be no more than 0.05%

 

4939

TOCOPHERYL LINOLEATE

E

Only for use in topical medicines for dermal application.

 

4940

TOCOPHERYL NICOTINATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration must not exceed 0.3%.

 

4941

TOLU BALSAM

A, E, H

 

4942

TOLUENE

E

The residual solvent limit for toluene is 8.9 mg per maximum recommended daily dose.

The concentration in the medicine must be no more than 0.089%.

 

4943

TOLYL ALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4944

TOLYLALDEHYDE GLYCERYLACETAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4945

TOMATO

E

 

4946

TONKA

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4947

TONKA BEAN EXTRACT

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4948

TONONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4949

TOXICODENDRON DIVERSILOBUM

H

Only for use as an active homoeopathic ingredient. 

 

4950

TOXICODENDRON PUBESCENS

H

Only for use as an active homoeopathic ingredient.

The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Toxicodendron pubescens.

 

4951

TOXICODENDRON RADICANS

A, H

The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Toxicodendron radicans.

 

4952

TOXICODENDRON SUCCEDANEUM

H

Only for use as an active homoeopathic ingredient. 

 

4953

TRACHELOSPERMUM JASMINOIDES

A, E, H

 

4954

TRACHYSPERMUM AMMI

A, E

Only for use in oral medicines when the plant part is fruit or seed.

The medicine requires the following warning statements on the medicine label:

- (PREGNT) 'Not recommended for use by pregnant and lactating women' (or words to that effect)

- (PREGNT2) 'Do not use if pregnant or likely to become pregnant' (or words to that effect).

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4955

TRAGACANTH

A, E

 

4956

TRAMETES VERSICOLOR

A, H

 

4957

TRAMETES VERSICOLOR PROTEOGLYCAN CONCENTRATE

A, H

Only for use in oral medicines.

 

4958

TRANS,TRANS-2,4-DECADIEN-1-AL

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4959

TRANS,TRANS-2,4-HEXADIENAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in the medicine must be no more than 1%.

The maximum daily dose must provide no more than 13.5 mg of Trans,Trans-2,4-Hexadienal.

 

4960

TRANS-1-(2,4,4-TRIMETHYL-2-CYCLOHEXEN-1-YL)-2-BUTEN-1-ONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4961

TRANS-2-DECENAL

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4962

TRANS-2-DODECENAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4963

TRANS-2-HEPTEN-1-AL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4964

TRANS-2-HEXENAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4965

TRANS-2-HEXENOIC ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4966

TRANS-2-HEXENOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4967

TRANS-2-HEXENYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4968

TRANS-2-HEXENYL PHENYLACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4969

TRANS-2-HYDROXYCINNAMIC ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4970

TRANS-2-OCTENAL

E

trans-2-Octenal must only be included in medicines when in combination with other permitted ingredients as a fragrance proprietary excipient formulation.

The total concentration of the fragrance proprietary excipient formulation containing trans-2-octenal must not be more than 1% of the total medicine.

 

4971

TRANS-2-UNDECENAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4972

TRANS-3-HEXENOIC ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4973

TRANS-4-DECENAL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4974

TRANS-8-(1-METHYLETHYL)-1-OXASPIRO(4.5)DECAN-2-ONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4975

TRANS-ETHYL 2-OCTENOATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4976

TRANS-METHYL-2-HEXENOATE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4977

TREACLE

E

When for oral or sublingual use, sucrose is a mandatory component of treacle.

 

4978

TREEMOSS ABSOLUTE

E

Permitted for use only in combination with other permitted ingredients as part of a fragrance proprietary excipient formulation.

When included in a medicine for use on the lips the concentration of treemoss absolute must be no more than 0.02%.

When for dermal use or use on the hair the concentration of treemoss absolute must be no more than 0.1%

The total fragrance proprietary excipient formulation in a medicine must be no more than 1%.

 

4979

TREFRIW WELLS MINERAL WATER

A

When for internal use, iron is a mandatory component of Trefriw Wells mineral water.

Solid dosage forms containing more than 5 milligrams of elemental iron in each dosage unit are required to have a child resistant closure.

Liquid Preparations containing more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure.

Only able to be used when presented in single use sachets for therapeutic use as an iron supplement.

 

4980

TREHALOSE DIHYDRATE

E

When for oral use and the quantity of trehalose dihydrate per maximum recommended daily dose exceeds 20 grams, the quantity of trehalose dihydrate must be declared on the label.

 

4981

TREMELLA FUCIFORMIS

A, H

 

4982

TRIACETIN

E

 

4983

TRIACONTANYL PVP

E

Only for use in topical medicines for dermal application.

 

4984

TRIADICA SEBIFERA

A, H

 

4985

TRIBASIC POTASSIUM PHOSPHATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of tribasic potassium phosphate.

When used in a solid medicine containing this ingredient, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid medicine containing this ingredient, the pH of the medicine must be no more than 11.5.

 

4986

TRIBASIC SODIUM PHOSPHATE

E

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

 

4987

TRIBEHENIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 6%.

 

4988

TRIBEHENIN PEG-20 ESTERS

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 6%.

 

4989

TRIBULUS TERRESTRIS

A, E, H

 

4990

TRIBUTYL ACETYLCITRATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4991

TRICALCIUM PHOSPHATE

E

 

4992

TRICAPRYLIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4993

TRICAPRYLYL CITRATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 7%.

 

4994

TRICETEARETH-4 PHOSPHATE

E

Only for use in topical medicines for dermal application.

 

4995

TRICHLOROMETHYLPHENYLCARBINYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4996

TRICHODERMA VIRIDE

A, E, H

 

4997

TRICHOSANTHES KIRILOWII

A, E, H

 

4998

TRICLOSAN

E

The concentration in the medicine must be no more than 1%.

 

4999

TRICYCLODECENYL PROPIONATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

5000

TRIDECANAL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

5001

TRIDECETH-4 PHOSPHATE

E

Only for use in topical medicines for dermal application.

 

5002

TRIDECETH-6

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.5%.

 

5003

TRIDECYL ALCOHOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used as in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

5004

TRIDECYL BEHENATE

E

Behenic acid is a mandatory component of Tridecyl behenate.

Only for use in topical medicines for dermal application.

 

5005

TRIDECYL NEOPENTANOATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 23%.

 

5006

TRIDECYL SALICYLATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. 

The concentration in the medicine must be no more than 5%.

 

5007

TRIDECYL STEARATE

E

Only for use in topical medicines for dermal application.

 

5008

TRIDECYL TRIMELLITATE

E

Only for use in topical medicines for dermal application.

 

5009

TRIETHOXYCAPRYLYLSILANE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 1%.

 

5010

TRIETHYL CITRATE

E

 

5011

TRIETHYLENE GLYCOL

E

 

5012

TRIFOLIUM PRATENSE

A, E, H

 

5013

TRIFOLIUM REPENS

A, H

 

5014

TRIGONELLA FOENUM-GRAECUM

A, E, H

 

5015

TRIHYDROXYPALMITAMIDOHYDROXYPROPYL MYRISTYL ETHER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.02%.

 

5016

TRIHYDROXYSTEARIN

E

Only for use in topical medicines for dermal application.

 

5017

TRIISOCETYL CITRATE

E

Only for use in topical medicines for dermal application.

 

5018

TRIISODECYL TRIMELLITATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

5019

TRIISONONANOIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

5020

TRIISOSTEARIN

E

Only for use in topical medicines for dermal application.

 

5021

TRILAURIN

E

Only for use in topical medicines for dermal application.

 

5022

TRILISA ODORATISSIMA

A, H

 

5023

TRILLIUM ERECTUM

A, H

 

5024

TRIMETHOXYCAPRYLYL SILANE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.25%.

 

5025

TRIMETHYL HYDROXYPENTYL ISOBUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

5026

TRIMETHYL UNDECYLENIC ALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

5027

TRIMETHYL-BICYCLO-HEPTANE-SPIROCYCLOHEXENONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

5028

TRIMETHYLBENZENEPROPANOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

5029

TRIMETHYLHEXANOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

5030

TRIMETHYLOPROPANE TRIOCTANOATE

E

Only for use in topical medicines for dermal application.

 

5031

TRIMETHYLPENTANEDIOL/ADIPIC ACID/GLYCERIN CROSSPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

5032

TRIMETHYLSILOXYSILICATE

E

Only for use in topical medicines for dermal application.

 

5033

TRINITROPHENOL

H

Only for use as an active homoeopathic ingredient.

The total concentration of trinitrophenol in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.

 

5034

TRIOCTANOIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

5035

TRIOCTYLDODECYL CITRATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 12%.

 

5036

TRIOLEIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

5037

TRIOSTEUM PERFOLIATUM

A, H

 

5038

TRIOXAUNDECANEDIOIC ACID

E

 

5039

TRIPEPTIDE-1

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.002%.

 

5040

TRIS-BIPHENYL TRIAZINE

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 10%.

When used topically, the dosage form must not be spray.

When used in primary sunscreen products, the following warning statements are required on the label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

5041

TRISILOXANE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 40%.

 

5042

TRISODIUM EDETATE

E

Only for use in topical medicines for dermal application.

 

5043

TRISODIUM ETHYLENEDIAMINE DISUCCINATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.2%.

 

5044

TRISODIUM NTA

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.005%.

 

5045

TRISTEARIN

E

 

5046

TRITICUM AESTIVUM

A, E, H

Gluten is a mandatory component when the plant part is seed and the route of administration is other than topical and mucosal.

 

5047

TRITICUM DURUM

A, E, H

Gluten is a mandatory component when the plant part is seed and the route of administration is other than topical and mucosal.

 

5048

TRIUNDECANOIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 11.2%.

 

5049

TROLAMINE

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 5%.

 

5050

TROLAMINE LAURIL SULFATE

E

Only for use in topical medicines for dermal application.

 

5051

TROLAMINE SALICYLATE

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 12%.

When used in primary sunscreen products, the following warning statements are required on the label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

5052

TROLLIUS CHINENSIS

A, H

 

5053

TROMETAMOL

E

 

5054

TROMETAMOL HYDROCHLORIDE

E

 

5055

TROPAEOLUM MAJUS

A, E, H

 

5056

TROPICAL RATTLESNAKE

H

Only for use as an active homoeopathic ingredient.

 

5057

TROPOLONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.01%.

 

5058

TSUGA CANADENSIS

A, H

 

5059

TULIPA EDULIS

A, H

Colchicine is a mandatory component of Tulipa edulis.

The concentration of colchicine in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%.

 

5060

TURMERIC

E

Permitted for use only in combination with other permitted ingredients as a colour.

 

5061

TURNERA DIFFUSA

A, E, H

Beta-arbutin is a mandatory component of Turnera diffusa.

When for oral use, the maximum recommended daily dose must not provide more than 500 mg of beta-arbutin.

When for dermal application exclusively to the face:

a) the concentration of beta-arbutin in the medicine must not be more than 7%;

b) hydroquinone is a mandatory component; and

c) the concentration of hydroquinone must not be more than 10 mg/kg or 10 mg/L or 0.001%.

When for use other than oral or dermal application exclusively to the face, the concentration of beta-arbutin in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.

 

5062

TURNIP

E

 

5063

TURPENTINE OIL

A, E

Only permitted for use when turpentine oil is derived from sources other than mineral turpentine.

The concentration in the medicine must not be more than 25%.

 

5064

TYPHA ANGUSTIFOLIA

A, H

 

5065

TYPHA LATIFOLIA

A, H

 

5066

TYPHONIUM GIGANTEUM

A, H

 

5067

TYROSINE

A, E